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ABSTRACT
Objective
This project investigates ways of assessing Vulval Vestibulitis Syndrome (VVS), 
possible aetiological factors, and response to a range of treatments.
Materials and Methods
1. Data were collected and analysed to identify possible epidemiological 
characteristics and compared to existing evidence.
2. Technology (an algesiometer) was used to reliably assess patients, and quantify 
response to treatment.
3. Immunohistochemistry was used to determine whether VVS is an inflammatory 
condition.
4. Immunohistochemistry was also used to investigate the expression of oestrogen 
and progesterone receptors in the vulval tissue of women with VVS and biochemical 
techniques were used to investigate any relationship with serum oestradiol.
Results
The cohort of women fulfilling the criteria for VVS were aged 22 to 53 (mean age 34.6) 
and for some there appeared to be an association with use of the combined oral 
contraceptive pill (cOCP).
The algesiometer allowed quantification of pain, and improvement with treatment.
There appears to be an overall decreased expression of inflammatory markers in 
women with VVS.
There appears to be no correlation between serum oestradiol and VVS, however 
vulval tissue from women with VVS appears to express less oestrogen receptors, 
although there is no difference in the expression of progesterone receptors.
Discussion
VVS is a condition which appears to have well defined epidemiological characteristics, 
although subgroups may exist.
There is evidence that it is not an inflammatory condition, as previously thought, giving 
weight to the current argument that it is not an “itis” and the condition should be 
defined as localised provoked vulvodynia, as proposed by the International Society for 
the Study of Vulvovaginal Disease (ISSVD) at their congress in 2003.
The nomenclature and classification of vulval pain forever appears to be evolving. 
Since late 2003 the term Vulval Vestibulitis Syndrome is no longer recommended by 
the ISSVD, although it was the term in use at the time this work was performed. The 
patients were selected for the studies by fulfilling Friedrich’s criteria for W S , and 
therefore this term is used throughout this thesis
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CHAPTER ONE - INTRODUCTION
Embryology of the vulva
The vulva begins to develop in the third week of gestational development when the 
three germ layers, the ectoderm, mesoderm and endoderm, form in the embryo.
The cloacal membrane forms between the ectoderm and distal endoderm.
The primitive cloaca divides into the anterior urogenital portion and the rectal portion, 
separated by the urorectal septum. In the sixth week, the cloacal membrane breaks 
down anteriorly to leave the urogenital sinus, which is divided into three portions, the 
caudal end being the genital tubercle, from the fusion of the cloacal folds. The phallic 
portion of the urogenital sinus remains open and between 14 and 20 weeks the vagina 
opens into the pelvic portion, converting it into the vestibule.
The lateral genital swellings become visible and these ultimately evolve into the labia 
majora. The medial urethral folds develop into the labia minora.
The genital tubercle enlarges slightly to form the clitoris. (Langman 1990)
Presence of the XX chromosome and lack of Mullerian inhibiting substance allows the 
ovary to develop and it is thought that oestrogens produced by the primitive ovary 
stimulate the development of the external genitalia although this is still unclear 
(George 1988)
Differentiation between the sexes occurs by the tenth week.
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Anatomy of the vulva
The vulva comprises of the mons pubis, labia majora, labia minora, clitoris, vestibule 
of the vagina, bulb of the vestibule and the greater vestibular glands.
The anterior border of the vulva is the mons pubis which is the hair bearing skin and 
subcutaneous fat overlying the symphysis pubis. The lateral margins are the lateral 
aspects of the labia majora and the vulva is bounded posteriorly by the perineal body.
The labia majora extend posteriorly from the mons pubis and are the outer hair 
bearing folds of the vulva. Medial to these are the hairless folds of the labia minora. 
These join together posteriorly at the fourchette. Anteriorly they enclose the clitoris 
and the prepuce, the skin covering of the clitoris.
The labia majora merge into the perineum posteriorly.
The vulval vestibule is the area at the entrance to the vagina bounded by Hart's line, 
the junction between two different types of skin. It extends caudally from the hymenal 
rim and is bounded posteriorly by the fourchette. It extends anteriorly to border the 
urethral meatus. This is shown in Fig.1.1.
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Fig 1.1 The vestibule
There are two major glands opening into the vestibule, but Robboy (1978) described 
multiple openings appearing as tiny pits in the vestibular surface which may not be 
identified without colposcopic magnification.
Hunt (1942) makes reference to “glandulae vestibuli minores”, but the main glands of 
the vestibule are best recognised as the two paraurethral (Skene's) glands anteriorly, 
and the two major vestibular or Bartholin's glands posteriorly.
Each of these glands lead to a duct approximately two centimetres long.
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When in the lithotomy position these gland openings are visible at 5 and 7 o’clock. 
These glands are lobulated and contain multiple acini, lined with cuboidal epithelium 
and the ducts are lined with stratified transitional epithelium. The glandular secretion 
is clear, mucoid and alkaline and increases with sexual arousal.
The blood supply of the vulva includes the superficial external pudendal artery and 
deep external pudendal artery, both of which are branches of the femoral artery. 
These provide the main arterial supply for the labia majora.
The internal pudendal artery is a branch of the internal iliac artery and supplies the 
clitoris and labia as well as the muscles of the perineum.
It enters the perineum by passing through the lesser sciatic foramen and travels 
forwards with the pudendal nerve in Alcock's canal when it branches to supply the 
various aspects of the vulva.
Also contributing to blood supply is a branch of the inferior epigastric artery.
The venous drainage of the vulva is via veins accompanying the arteries described 
above.
The lymphatic drainage of the vulva is via lymph vessels which accompany the 
vessels. Drainage is to the superficial and deep inguinal groups of nodes.
The nerve supply of the vulva is derived from the roots of L1 and L2 via the 
genitofemoral nerve and S1 - 4.
The pudendal nerve is a branch of the sacral plexus (S2,3,4). It follows the course of 
the pudendal artery as it leaves the pelvis through the greater sciatic foramen and 
enters the perineum through the lesser sciatic foramen.
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From here it passes anteriorly via the pudendal canal (Alcock's canal) where it divides 
into three main branches: the inferior rectal nerve, the dorsal nerve of the clitoris and 
the perineal nerve. The perineal nerve supplies the muscles of the urogenital triangle 
and the posterior surface of the labia majora.
The ilioinguinal nerve derived from L1 enters the anterior abdominal wall and passes 
down the inguinal canal into the labia majora where its branches provide cutaneous 
supply for both the labia and the mons pubis. Further cutaneous supply to the labia is 
provided by the genital branch of the genitofemoral nerve which originates from the 
roots of L1 - 2.
The vestibule and the perineum are also supplied by the perineal branch of the 
posterior femoral cutaneous nerve.
The vulva has various sensory nerve endings. Meissners corpuscles are specialised 
tactile nerve endings that are particularly common in the clitoris. They consist of 
unmyelinated terminals of afferent nerve fibres and supporting cells that are thought to 
be modified Schwann cells. They are cylindrical in shape and measure about 150 
microns in length. They are located immediately under the epidermis.
Pacinian corpuscles are pressure receptors found in the deeper layers of connective 
tissue in the labia majora and in association with erectile tissue of the clitoris. They 
contain the termination of myelinated nerve fibres although the terminal part itself is 
unmyelinated. It is surrounded by layers of flat cells that are continuous with the 
endoneurium. They are large ovoid structures that measure about 1mm in their long 
axis.
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Histology of the vulva
The epidermis of the vulva is a stratified squamous epithelium, developed from the 
ectoderm. The dermis is developed from the mesoderm. In vertical sections the 
epidermis undulates due to the rete ridges at the dermal epidermal junction. 
Histologically the epidermis is described in 4 layers: a basal layer, a spinous or prickle 
cell layer which forms the majority of the epidermis, a granular layer and a horny layer. 
The vestibule however is covered with a non cornified stratified squamous epithelium 
ie. a mucous epithelium. Hart's line marks the border between the two types of 
epithelium.
Haematoxylin and Eosin stained section of the vestibule is shown in Fig 1.2.
The labia majora contain a thin layer of smooth muscle (equivalent to the Dartos 
muscle seen in the scrotum) and a large amount of subcutaneous fat.
The outer aspects have hair follicles but the inner aspects do not.
Sweat and sebaceous glands can be seen on both surfaces
The labia minora do not contain hair follicles. In the deeper epithelial layers the cells 
are pigmented. Unlike the labia majora there is no adipose tissue present but fine 
elastic fibres are visible as are numerous sebaceous glands in the stroma.
17
Fig 1.2 H&E section of the vestibule
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Within the vestibule, glandular structures are visible penetrating the stratified 
squamous epithelium. The greater vestibular glands are tuboalveolar structures that 
are mucus secreting.
The clitoris is composed of erectile tissue, similar to that of the penis, covered by a 
thin layer of epithelium containing numerous sensory nerve endings.
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Ultrastructure of the vulval vestibule
The epithelium of the vulval vestibule is non keratinised and nonpigmented. Hair 
follicles and sweat glands are absent and its appearance is more like mucosa than 
that of normal skin, and stains with iodine and toluidine blue.
Layers of the epithelium are not easily indistinguishable but in a study of the 
ultra structure of the vulva it is been divided into three layers.(Sargeant et al 1996)
The superficial cell layer is characterised by microridges that are not present 
elsewhere in the perineum. The surface cells are flattened and contain few 
organelles. Microvillous processes interdigitate between the surface cells and 
desmosomal junctions are short and less frequently seen here than in deeper layers. 
Nuclei are not uncommon and are spherical and often displace due to the presence of 
large deposits of glycogen.
The intermediate, or spinous cell layer, consists of polyhedral cells becoming 
increasingly flattened towards the surface. The deeper cells are rich in mitochondria 
and rough endoplasmic reticulum and Golgi regions are visible. The cytoplasm is 
characterised by the presence of free and poly-ribosomes and glycogen granules. 
Cytokeratin fibres form a diffuse network in the cytoplasm, leaving a clear zone around 
the nucleus.
The plasma membrane is highly convoluted and microvillous projections extend into 
the intracellular spaces between the desmosomal junctions.
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The basal layer gives the basement membrane an undulating contour. Cells are 
characteristically round or oval and have large oval nuclei with one or more nucleoli. 
Mitochondria, free ribosomes and endoplasmic reticulum are numerous. As in the 
intermediate layer a tonofilament network around the nucleus is visible. Projections of 
cytoplasm extend into the dermis and lymphocytes from the underlying dermis 
penetrate up into the epidermis.
It is interesting to note that a significant number of inflammatory and apoptotic like 
cells are present in the normal vestibule. It is thought that this may correlate with high 
cell turnover, similar to that seen in the buccal mucosa. (Squier et al 1976)
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Diseases of the vulva
The classification of vulval disease has long been disputed and is regularly updated. 
(Ridley 1988) Fashionable terms become outmoded as our knowledge and 
understanding of vulval disease increases. (MacLean 1991)
The International Society for the Study of Vulvovaginal Disease (ISSVD) was founded 
to address these problems and to give clinicians the opportunity to meet and share 
knowledge.
In 1998 the ISSVD updated its classification of non neoplastic vulval disorders 
(Appendix 1.1) and proposed change in nomenclature relating to other pathology of 
the vulva was further debated at the international scientific meeting in 2003.
Vulval disease falls into three simplified categories: non neoplastic disease, neoplastic 
disease and vulval pain syndromes.
Classification of Vulval Pain
Vulval pain is a complex and poorly understood area of vulval disease.
Vulvodynia was described in the Presidential Address of the 1985 meeting of the 
ISSVD as “a syndrome of unexplained vulvar pain, psychologic disability and sexual 
dysfunction” (Lynch 1985) and unfortunately this is probably still appropriate although 
our recognition, if not knowledge of the underlying mechanisms, has improved.
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Vulval pain has had many names over the years. Dodson and Friedrich (1977) 
referred to psychosomatic vulvovaginitis and established the initial parameters of 
vulvodynia:
1 ) persistent symptoms of long standing duration
2 ) lack of demonstrable pathology
3) sexual inactivity as a direct result of symptoms
4) unsuccessful consultations with multiple physicians
5) allergy to many common vaginal preparations
6 ) reluctance to accept the suggestion of a psychophysiologic cause
7) emotional lability and dependence
These observations describe some of the characteristics of patients with vulvodynia 
but do not help in the classification of the diseases.
In the early eighties the term “burning vulva syndrome" was introduced (McKay 1984) 
following the report of a Task Force set up by the ISSVD.
This differentiated between vulvodynia and burning vulva syndrome, defined as 
vulvodynia for which no physical cause can be found, and discussed the differences of 
a patient who presents with pain as opposed to itch.(McKay 1985).
Although suggested that a generic term of vulval pain syndrome may encompass all 
patients, (Baggish et al 1995) the Latin translation of vulval pain, vulvodynia, is now 
universally accepted.
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The term vulvodynia is defined as chronic vulval discomfort, especially that 
characterised by the patient’s complaint of burning, stinging, irritation or rawness. 
(McKay 1988) Subsets of vulvodynia at this time were classified as:
1 ) vulvar dermatoses
2 ) cyclic candidiasis
3) vulvar vestibulitis
4) squamous papillomatosis
5) essential vulvodynia
In 1991 the ISSVD took this further and classified vulvodynia as:
1 ) vulvar dermatoses
2 ) cyclic vulvodynia
3) vestibular papillomatosis
4) vulvar vestibulitis
5) essential (dysaesthetic) vulvodynia
6 ) idiopathic vulvodynia
The vulval dermatoses classically present with pruritus and not pain and will not be 
examined in detail in this chapter.
Cyclic vulvodynia relates to vulval pain that is recurrent rather than persistent and an 
association with the menstrual cycle can be identified. Infection such as chronic 
candidiasis, herpes simplex virus or bacterial vaginosis are common features.
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Vestibular papillom atosis refers to the appearance of microscopic papillae over the 
surface of the vestibule. Often misdiagnosed as “microwarts”, these papillae have 
been subjected to a wide variety or both medical and surgical treatments, but are now 
regarded as a normal variant. Therefore the only treatment required is reassurance. 
An example of vestibular papillomatosis is shown in Fig.1.3
Fig 1.3 Vestibular papillae
Vulval ves tibu litis  refers to a specific syndrome causing vulvodynia. This will be 
discussed in greater depth later in this chapter.
Essential (dysaesthetic) vu lvodynia typically occurs in older women
It is an intense burning of the vulva with no physical signs. The burning is persistent
and unrelenting but pruritus is absent. This pain is often compared to glossodynia or
24
post herpetic neuralgia and as a consequence of this the same treatment protocols 
have been applied. (Watson et al 1982) Often low dose tricyclic antidepressants will 
provide total relief, but sometimes much larger doses are necessary. (McKay 1993)
Idiopathic vulvodynia incorporates unusual cases of vulval pain that are not 
classified by the major subgroups.
Infective conditions of the vulva are not covered by these classifications but are 
common causes of vulval pain as opposed to itch. (Reid et al 1995) These are not 
often seen in the vulval clinic as they tend to be treated elsewhere, most commonly in 
the genito-urinary medicine clinic.
Although many of these infections are thought to be vaginal involvement of the vulva 
in many cases is inevitable. This includes conditions such as genital herpes, 
trichomoniasis, candidiasis, herpes zoster, chancroid and amoebasis.
As the vulva is a hair bearing area, folliculitis and subsequent abscess formation 
may occur, but these can normally be treated simply with oral antibiotics.
Vulvodynia continued to be debated and there were proposals to no longer use this 
term.
At the 2003 ISSVD meeting in Brazil, it was voted to return to use of the well accepted 
term of vulvodynia, with a slightly modified definition, of “Vulvar discomfort, most often 
described as burning pain, occurring in the absence of relevant visible findings or a 
specific, clinically identifiable neurologic disorder.”
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The classification of vulvodynia, based on the site of the pain was also introduced. 
This is the most recent classification of vulval pain, (2003):
A. Vulvar pain related to a specific disorder
1. Infectious (e.g.candidiasis, herpes)
2. Inflammatory (e.g. lichen planus, immunobullous disorders)
3. Neoplastic (e.g. Paget’s disease, squamous cell carcinoma)
4. Neurologic (e.g. herpes neuralgia, spinal nerve compression)
B. Vulvodynia
5. Generalized
a) Provoked (sexual, nonsexual, or both)
b) Unprovoked
c) Mixed (provoked and unprovoked)
6. Localized (vestibulodynia, clitorodynia, hemivulvodynia)
a) Provoked (sexual, nonsexual, or both)
b) Unprovoked
c) Mixed (provoked and unprovoked)
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Vulval Vestibulitis Syndrome
History
Vulval pain is not a condition purely of the modern age. Although the term vulval 
vestibulitis syndrome (VVS) has only been in use for over a decade, the clinical entity 
we currently call vestibulitis has been making appearances in the literature for over a 
century.
The earliest record appears to be in 1889 when Skene recognised hyperaesthesia or 
excessive tenderness of the vulva without pruritus and the absence of external 
manifestations. However during examination he said “when the examining finger 
comes into contact with the hyperaesthetic part, the patient complains of pain which is 
sometimes so great as occasion her to cry out.”
In 1891 in their text Thomas and Munde commented on hyperaesthesia of the vulva 
and described it as “ a malady which consists in an excessive sensibility of the nerves 
supplying the mucous membrane.”
No further comment is made until 1928 when Kelly described “exquisitely sensitive 
deep red spots in the mucosa of the hymenal ring as a fruitful source of dyspareunia.” 
He commented that these areas were so tender as to make a pelvic examination 
essentially impossible.
The vestibular glands were described in detail in a variety of anatomy texts over the 
next forty years but no connection was made with the previous clinical descriptions. 
(Hunt 1942, Dickinson 1949, Friedrich 1973)
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In 1976 a series of 30 cases was presented of women who had red spots localised to 
the posterior vestibule and dyspareunia as a major symptom. Histologically there was 
an abundance of plasma cells but the authors did not associate this with the glandular 
element of the vestibule (Pelisse and Hewitt 1976).
Plasma cell balanitis of Zoon was already recognised and in a review of the literature 
"vulvitis circumscripta plasmacellularis” was suggested as a cause of vulval pain. 
However this also was not associated with the vestibular glands (Davis 1983).
In 1983 Friedrich published his description of the vestibule and introduced the term 
vestibular adenitis. He described the vulval vestibule as an active and reactive area 
and vestibular adenitis as a condition when the minor vestibular glands and 
sebaceous glands become inflamed which produces a painful erythematous vestibule. 
When pressure is applied to these spots pain is provoked. He suggested that multiple 
glands become involved and the spots coalesce into a diffuse, tender erythema that 
may extend to involve a considerable part of the vestibule. He proposed that in 
chronic cases of vestibular adenitis that mucus glandular elements have been 
replaced by squamous metaplasia and only the plasma cell rich infiltrate remains. 
Because of this squamous metaplasia he emphasised the importance of not mistaking 
the condition for carcinoma in situ (Friedrich 1983).
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This view was reiterated when he combined data with Woodruff and commented that 
the diagnosis is made due to the lack of normal stratification in the epithelium. They 
described vestibular adenitis as a newly recognised syndrome of severe dyspareunia 
caused by inflammation of the minor vestibular glands (Woodruff and Friedrich 1985).
At the same time as the term vestibular adenitis was introduced Woodruff and 
Parmley (1983) described a condition of tiny erythematous foci immediately lateral to, 
and circumferentially involving the hymenal ring. The hymenal ring was constricted 
and rigid with associated oedema and these foci were tender on palpation. No other 
physical abnormalities were seen and many of the patients described had been 
labelled as having psychiatric problems. The authors suspected that these signs and 
symptoms were caused by a chronic infection of the minor vestibular glands.
The term focal vulvitis was then introduced (Peckham et al 1985). This was defined 
as “a unique syndrome characterised by severe and persistent dyspareunia and 
presence of one to eleven minute, exquisitely tender areas of focal inflammation or 
ulceration on the mucosa of the vestibule.” It was observed that three quarters of the 
lesions were around the major (Bartholins) vestibular glands, or between them 
posteriorly.
A case definition for focal vulvitis was set out with criteria including vulval pain, 
dyspareunia or pain with tampon insertion associated with:
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1) one or more minute exquisitely sensitive focal inflammatory lesion located in the 
vestibule.
2) no identifiable cause eg. herpes, bacterial or candidal vaginosis or pemphigoid.
Peckham et al described mucosal changes (1985). 22% of the cohort had minute 
discrete ulcers in the mucosa, some patients had superficial denuded mucosa or 
appeared split and tiny indolent ulcers were deep within the crypts. It was thought that 
these were secondary to inflammation but not necessarily infection.
The review of their histology did not reveal excessive plasma cells leading them to 
state that they had excluded the possibility that these women had Zoon's vulvitis, but 
had a separate condition, focal vulvitis.
A year later minor vestibular gland syndrome was introduced (Marinoff and Turner 
1986). This was described as a specific clinical entity found in young women with a 
previous history of vaginal candidiasis.
The criteria for diagnosis included introital dyspareunia, absence of active infection, 
erythema around the orifices of the minor vestibular glands and exquisite tenderness 
over these gland openings.
The aetiology of this was unrecognised but the authors concluded that it was unlikely 
that a delayed hypersensitivity reaction to Candida or an irritant or allergic reaction to 
vehicles in vaginal cream were responsible.
In 1987 Friedrich argued that the terms previously used should no longer apply.
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Having reviewed the histology he concluded that since secretory acini and gland ducts 
were not intrinsically involved by inflammation and the presence of glandular elements 
in the involved foci was not constant that adenitis was not an appropriate description. 
He also suggested that the term focal vulvitis was too broad and could apply to any 
part of the vulva involved in local irritation. Instead he proposed the term Vulval 
Vestibulitis Syndrome (VVS) and laid out strict criteria to be fulfilled before the 
diagnosis could be made. These criteria are now known as Friedrich's triad.
VVS is a constellation of histological, subjective and objective criteria:
1) severe pain on vestibular touch or attempted vaginal entry.
2) tenderness to pressure localised within the vestibule.
3) physical findings confined to vestibular erythema of varying degrees.
This term and definition is in general use today and was approved by the ISSVD, who 
agreed, “vulval vestibulitis syndrome does not include symptoms associated with 
acute inflammatory conditions or with immediate post operative changes.” They have 
suggested that the specialised epithelium of the vestibule and minor vestibular glands 
may make this area particularly sensitive to morphological changes that may influence 
the development of vulvodynia.
The terminology is still a matter of great debate and the latest suggestion from the 
ISSVD is “localized provoked vulvar dysesthesia” (2001), although W S  still appears 
to remain the common term of use.
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Since Friedrich's definition it has been postulated that there may be subsets of vulval 
vestibulitis.
In patients whose dyspareunia invariably involved the greater vestibular gland duct 
with or without sensitivity extending to adjacent sites may make up one subgroup of 
vulval vestibulitis (Michelwitz et al 1989).
Vestibulodynia is proposed as a subset of vestibulitis in women who fulfil Friedrich's 
triad but who also have a persistent pain of vestibular origin (Bornstein et al 1997).
Diagnosis of vulval vestibulitis syndrome
The diagnosis of this condition can be made following the taking of a thorough history 
and after detailed physical examination. Classically the patient is a young woman who 
previously has had no vulval symptoms. She often presents to a specialist vulval 
clinic after many months or years of symptoms. It is not uncommon for the clinic to be 
among the last of many consultations, having seen many clinicians in a variety of 
departments. Often she has been misdiagnosed, with the most common diagnosis 
being chronic candidiasis. It is not unusual that she has been told that there is nothing 
physically wrong and that her condition is psychosomatic, and may have been offered 
psychosexual counselling.
Her symptoms can be sufficiently severe that it has had a major impact on her lifestyle 
and may well have contributed to the breakdown of relationships.
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She is often angry, cynical and disillusioned with the medical profession and it is 
important to build a good relationship with these patients quickly, although this may 
not always be easy.
The typical story is of a perfectly normal sexual relationship until the onset of 
symptoms. Normally she can identify the point at which the symptoms started and 
often the onset was extremely quick. She describes pain at the point of penetration 
during intercourse. Often if intercourse is possible she describes that the initial pain 
wears off and she does not complain of deep dyspareunia. Some patients also 
complain of an intense vulval burning following intercourse that may last for hours, if 
not days.
As a result of these problems intercourse has become less frequent, or impossible. If 
specifically asked about tampon use, often patients will find this uncomfortable and 
many have abandoned their use. In severe cases certain items of clothing, such as 
tight jeans may have become uncomfortable to wear. In addition certain other 
activities, such as horse riding may exacerbate the symptoms.
Many patients have tried multiple treatments, both conventional and the more unusual, 
with little success. Examination prior to referral has usually been reported as 
unremarkable. This is where the specialist facilities of a vulval clinic can enable the 
examining doctor to make a diagnosis.
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Diagnosis of VVS with the naked eye in a routine clinic on a normal couch is difficult, 
but appropriate lighting and adequate exposure on a colposcopy couch or chair makes 
the process much easier, and if closed circuit television is attached to the colposcope 
enables to patient to see problem areas.
Colposcopy of the vulva is now well recognised (Byrne et al 1989). However, with 
vulval pain syndromes, often physical findings are minimal or non existent (Reid et al 
1988). Equally it has been recognised that signs such as vestibular erythema can be 
identified in healthy women with no vulval symptoms (van Beurden et al 1997). 
Examination of the vulva should be conducted in a private clinical area, ideally a 
separate room and not a curtained off area. Adequate lighting should be available. 
Optimum examination is in the lithotomy position and a tilting chair is ideal to achieve 
this. The whole vulva should be carefully examined, including the groin and perianal 
areas, both with the naked eye and with the aid of the colposcope.
The use of KY jelly may be of assistance in minimising the reflection of light in hair 
bearing areas (Reid and MacLean 1995).
Other vulval lesions, as previously discussed may be visualised with the use of acetic 
acid or toluidine blue, but this is not necessary in the diagnosis of vulval vestibulitis 
syndrome.
In W S  the labia will have normal appearance. Physical appearance of the vestibule 
may be variable. The most common colposcopic finding is enlargement and erythema 
of the orifices of both the paraurethral and posterior vestibular glands, although each
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may be seen independently. Erythema of the vestibule is one of the defining criteria, 
but as suggested in the original definition the degree of erythema may be variable.
In a trial investigating the reliability of diagnosis and evaluation of the current 
diagnostic criteria of VVS it was noted that “inter rater” agreement and test -  retest 
reliability for the presence or absence of erythema was poor, suggesting it may not be 
a significant contribution to diagnostic decision making (Bergeron et al 2001). Support 
for this is provided by Friedman (1995) who found normal controls not significantly 
different from VVS women in terms of presence of erythematous lesions.
Touching of the vestibular glands will produce exquisite tenderness, evoking the pain 
experienced at attempted intercourse. Traditionally this has been referred to as “Q tip 
tenderness” as a cotton bud is rolled over the entrance to these glands (Goetsch
1991). Bergeron et al (2001) found that VVS can be reliably diagnosed in women with 
dyspareunia, and the pain can be rated and described in a consistent fashion by these 
women. However, pain assessment at examination between different gynaecologists 
varied, as a result of different degrees of pressure applied.
It has been found that a vulval algesiometer provides a more accurate assessment of 
this tenderness. (Eva et al 1999) The use of the vulval algesiometer will be discussed 
in greater detail in chapter 2.
A full set of swabs should be taken to exclude infective causes of acute vulvovaginitis, 
eg. Candida, chlamydia, gonorrhoea, trichomonas, bacterial vaginosis. If the history of 
entry dyspareunia, physical findings of erythema around the vestibular glands and 
tenderness when pressure is applied to these openings are present, then the 
diagnosis of vulval vestibulitis syndrome can be made.
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Pathology of vulval vestibulitis syndrome
The first attempt to characterise the pathology of W S  was in a series of 41 patients 
(Pyka et al 1988). A wide variety of pathological investigations were performed on the 
tissue obtained from patients who had undergone surgical excision of the vestibule. 
Sections stained by haematoxylin and eosin were examined for histopathological 
features. The predominant feature was a mixed chronic inflammatory infiltrate. 75% 
of sections had lymphocytes present and 75% had plasma cells, although they were 
never the predominant cells. Histiocytes were present in 30% of the samples and 
polymorphonuclear leucocytes in 25%. Eosinophils were extremely rare.
Unlike previous clinical descriptions, there was never any evidence of ulceration or 
necrosis. No evidence of atypia of any cell was present. The inflammatory infiltrate 
was often perivascular and in the majority of the specimens was categorised as mild 
to moderate. Inflammation in the minor vestibular glands was periglandular and was 
never seen to cause an adenitis by involving the gland itself, thus agreeing with 
Freidrich's argument that vestibular adenitis was no longer an accurate description of 
this condition.
All minor vestibular glands showed some degree of metaplasia with some having 
almost been replaced by squamous metaplasia.
The authors described vestibular clefts, which had been formed by the coalescence of 
clusters of adjacent glands, which had undergone squamous metaplasia.
These clefts almost took on the appearance of the surrounding vestibular epithelium. 
The lymphocyte population that was so prevalent, was almost exclusively
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T lymphocytes. B lymphocytes were absent in all but one of the specimens.
Staining with toluidine blue for mast cells proved positive in less of the study 
population than in the control group. Immunofluoresence staining was performed for 
Ig G, Ig A, Ig M, complement and fibrin. All results were non-specific. Organisms 
were looked for using silver methanamine stain for fungus, Gram staining, Brown -  
Brenn stain, Acid fast stain and Dieterle silver stain specific for spirochetes but all 
proved negative.
In summary the study could not define a characteristic histopathology for vulval 
vestibulitis, and only a non-specific chronic inflammatory infiltrate had been revealed.
In a review of 114 non neoplastic vulval biopsies only 11 patients had vestibulitis and 
the authors concluded from this that the clinical syndrome of vestibulitis did not have a 
specific histological picture. The biopsies showed non-specific inflammation, mild 
hyperplasia or were normal. (O'Keefe et al 1995)
A further series of 24 patients was published. (Furlonge et al 1991) They found the 
most common histopathological pattern was epithelial hyperplasia accompanied by an 
acute or chronic inflammatory cell infiltrate in the lamina propria.
Specifically they found koilocytosis in 2, neutrophilic vasculitis in 1 and acute 
inflammation of a sebaceous gland in 2 specimens. All stains for microorganisms 
were negative. The authors suggested that due to the non-specific pattern of the 
pathology, VVS may be the end point of a number of pathological processes.
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A different argument was put forward following publication of a series of 16 patients. 
(Chaim et al 1996) Following staining with Giemsa, large numbers of mast cells were 
found in the specimens of patients with a diagnosis of vulval vestibulitis. Mast cells 
were not seen in the control tissue. Apart from this finding there was not a great 
difference compared to the other studies, showing chronic inflammation, 
parakeratosis, hyperkeratosis, oedema, koilocytosis and acanthosis. The authors 
suggested that mast cells play a role in the aetiology of the symptoms of VVS and 
made comparisons with the role the mast cells are known to have in interstitial cystitis. 
They suggested that vestibular pain and inflammation is mediated by a similar 
method, as in interstitial cystitis, where prostaglandins and histamine are released by 
mast cells “recruited” to a local site by increased numbers of unmyelinated afferent 
and sympathetic efferent nerve fibres. These fibres exert a tropic effect on the mast 
cell density. This would also explain the erythema, caused by vasoactive mediators 
found in mast cells. These findings however conflict with those of Pyka et al (1988) 
where staining for mast cells was not as marked.
More recently, in a series of 12 patients, (Chadha et al 1998) no great difference was 
found compared to previous studies. This study showed a chronic inflammatory 
infiltrate in the dermis that extended into the epidermis in 66% of the samples. 
Predominant cells again were lymphocytes and immunophenotyping of the 
lymphocytic infiltrate showed mainly T cells with a small number of B cells. The T 
helper/ T suppresser ratio was normal. Other cells identified were plasma cells, mast 
cells and occasionally monocytes.
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The minor vestibular glands were associated with a periglandular inflammatory 
infiltrate, which, as previously recognised, did not invade the gland itself. Squamous 
metaplasia was present in a third of the specimens, which was a lower rate than had 
previously been quoted. Reactive changes were seen in the mucosal squamous 
epithelium. Epithelial hyperplasia was seen in 83%, hyperkeratosis and parakeratosis 
in 50% and no ulceration was seen in any of the samples. In situ hybridisation for 
human papilloma virus subtypes 6, 11, 16 and 18 were negative but the association 
between HPV infection and VVS will be addressed in more detail later in this chapter.
In summary, current literature is ambiguous and there are no defining pathological 
features to sustain a diagnosis. The changes seen in the histopathology of vulval 
vestibulitis syndrome remain that of non-specific chronic inflammation with no 
characteristics features.
The challenge is to find more useful diagnostic parameters to allow better reliability of 
diagnosis.
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Epidemiology of vulval vestibulitis syndrome
Various studies have been conducted in an attempt to define the population that this 
condition affects. The majority have compared characteristics of their study 
populations to a group of normal controls to see whether any dramatic difference is 
apparent. Unfortunately this does not appear to be the case, although certain patterns 
have developed.
The most obvious characteristic is that W S  seems to mainly affect the Caucasian 
population. Although this could be expected in a Scandinavian population (Sjoberg et 
al 1997) it is more unusual in North American studies that have a multicultural general 
population. (Goetsch 1991, Peckham et al 1985, Mann et al 1992, Schover et al
1992) Therefore there was a need for a London study where there is a varied 
multiethnic population.
Classically this is a condition of young premenopausal women normally presenting in 
their twenties or thirties, although the symptoms of the condition may have occurred 
some time before presentation.
The length of symptom duration reflects the fact that a visit to specialist may be at the 
end of a long search via many clinicians for answers. Usually duration of symptoms is 
at least a year, but median duration varies from 23 months (Mann et al 1992) to 8.5 
years. (Goetsch 1991) The majority of patients in all studies are nulliparous.
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Whether this is reflection of the fact the condition affects younger women, or whether 
the impact of their symptoms is enough to seriously impair their ability to tolerate 
penetrative intercourse is unclear. Some authors class post-partum vestibulitis as a 
subset of VVS (Goetsch 1991) but there is little evidence elsewhere to support this.
Age of first intercourse appears in concordance with the general population although 
one study found an increase rate of vestibulitis (relative risk 3.3) in the group of their 
cohort who had first intercourse under the age of 16. (Bazin et al 1994)
Number of lifetime partners varies minimally between studies (median 3.6 (Sjoberg et 
al 1997) and 5 (Peckham et al 1985), but this is not a syndrome of promiscuous 
women.
Contraceptive use analysis shows that the oral contraceptive pill (OCP) is the most 
commonly used form of contraception, and Bazin et al 1994 showed and increased 
relative risk of developing VVS in women who had used the OCP before the age of 17 
and suggested that it’s use may be involved in the aetiology of W S . However it is 
used by less than half of the women in most cohorts.
In general there are few characteristics of women who have W S  that set them apart 
from any other gynaecological population.
In conclusion, from the studies looking at epidemiology, we can surmise that this is a 
condition that affects mainly white women in their twenties and thirties, who are likely 
not to have children.
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Aetiology of Vulvaf Vestibulitis Syndrome
Since the discovery of VVS as a clinical entity, regardless of name, the search began 
to discover aetiological agents that may explain the unusual course of the condition. 
Various avenues have been pursued and publications have produced a range of 
possibilities.
Attempts have been made to sub classify VVS as different pathologies in order to 
explain aetiology further. Acute vulval vestibulitis syndrome could be caused by any 
infective cause of vulvovaginitis, or by contact irritants such as soaps, latex,spermicide 
and douches. Removal of these precipitating factors could resolve the condition. 
Chronic VVS could be caused by chemical therapeutic agents such as antiseptics or 
applications of local antifungals or antibiotics. Destructive therapeutic agents such as 
cryosurgery, podophyllin or tri-chloroacetic acid could precipitate symptoms, as could 
drug reactions (Marinoff and Turner 1991).
Another suggested subdivision is that W S  is either primary or secondary (Goetsch 
1991). This author argued that the syndrome exhibits bimodal occurrence that is 
either primary, where the patient has never been able to have painfree intercourse, or 
acquired later in life after a precipitating factor, where previous painfree intercourse 
had been possible.
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Characteristics of primary VVS are patients that give a history of worse pain compared 
to those with secondary VVS and there is a strongly positive family history, affecting 
the patient’s immediate female relatives. An increased proportion of nulliparous 
women are found in this group.
Secondary VVS is often post partum. There is a negative association between sisters 
and specific causes are often implicated, e.g. group B Streptococcus, although this is 
a vaginal commensal, carried by 14% of the pregnant population, and may not be 
significant.
One study found 44% of their cohort experienced symptoms with first intercourse, and 
therefore were classified as primary W S  (Bazin et al 1994).
They postulated that W S  was exacerbated by loss of protective vaginal mucus. They 
hypothesised that primary VVS was due to a physiological malfunction of the minor 
vestibular glands producing inadequate amounts, or impaired quality of mucus and 
that secondary W S  was when the mucus production was affected by an acquired 
cause. An example of such was when the quality and quantity of mucus is modified 
by hormones.
Argument against the idea of primary and secondary W S  is provided in a study where 
only 6 of 50 women experienced symptoms with first intercourse and 1 with first use of 
tampons. The remaining 43 had normal relationship and lifestyle prior to the 
commencement of their symptoms (Peckham et al 1985).
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In fe c t iv e  c a u s e s
Probably the most extensively investigated possible aetiological factor is human 
papilloma virus (HPV). Histopathological studies revealed the presence of 
koilocytosis, previously considered to be an indicator of the presence of HPV.
The quoted incidence of koilocytosis in patients with VVS is variable, and ranges 
between 16 and 71%. Obviously a lot of women find the diagnosis of HPV, and the 
stigma of genital warts distressing, and so is important in these patients, who are 
already distressed, not to label them with an additional and unnecessary diagnosis.
It is not logical that HPV could cause W S , as HPV infection alone is normally 
painless, and even vulval warts do not usually produce the pattern of vulval pain seen 
in VVS.
The theory linking W S  and HPV was first proposed in a small study of just 7 women 
(Turner and Marinoff 1988). These authors looked for HPV DNA using Southern blot 
techniques and found evidence of the virus in all of their samples. However they were 
unable to subtype any of the HPV for the common subtypes seen in genital infection, 
(types 11, 16, 18 and 31) with the exception of one sample that was positive for HPV 
type 6. Histopathological examination of these specimens did not show koilocytosis in 
any of the samples. They proposed that HPV infection is one of the causes of 
vulvodynia and W S . They thought that the inflammatory response, in the form of a 
lymphohistiocytic infiltrate around the superficial capillaries, may be the beginnings of 
the body’s attempt to rid itself of virus and the syndrome was perhaps due to a 
problem with the local immune response.
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They concluded that the treatment of HPV infection, for example by interferon may 
cure introital dyspareunia.
A further study of 13 patients (Umpierre et al 1991) appeared to concur with this.
HPV was searched for using polymerase chain reaction (PCR) and dot blot 
hybridisation with a non-specific primer. They found HPV in 85% of the samples.
50% were types 16 and 18, the remainder were unidentified. They looked at patient 
response to alpha interferon, but found it only to be effective in half of the HPV 
positive patients. They concluded that although HPV appeared to have a role in the 
aetiology of VVS, HPV detection did not help in predicting which patients would 
respond to interferon.
Goetsch in the same year, in a much larger study did not find significant evidence to 
support this. Studies since then have contradicted the initial evidence.
A study of 31 women (Wilkinson et al 1993) used a PCR probe specific for HPV types 
6, 11, 16 and 18. They found koilocytosis in 5 patients and only 3 of these produced a 
positive result for HPV (types 11 and 16). The prevalence rate of 10% was similar to 
that seen in their control population. They argued that this difference compared to 
previous rates may be due to the fact that they did not probe for all known HPV types, 
but only for the most common ones seen in genital infection.
However two studies published shortly after this study produced similar results, both 
using PCR technology. One (Bazin et al 1994) quoted a prevalence of only 5.3% and
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the other failed to identify HPV in any of the 11 patients studied, including one who 
demonstrated koilocytosis (Bergeron et al 1994).
Only one study has looked specifically for other viral aetiology (Bornstein et al 1995). 
They looked at 86 women using PCR on frozen sections to investigate the presence of 
HPV, herpes simplex virus (HSV) and cytomegalovirus (CMV).
No evidence of HSV or CMV was found in any of the samples. The prevalence of 
HPV was 54% although was not typed for 6,11, 16, 18 or 33. They concluded that 
HPV is found in more than half of cases of W S .
It has been proposed that the variability in the rate of HPV infection could be due to 
the different methods used. DNA may be lost due to subtle differences in the 
extraction, and the search for specific types may bias results. With such conflicting 
reports, the evidence that HPV infection may be part of the aetiology of W S  is 
inconclusive.
The emphasis remained on an infective cause being the major aetiological factor, with 
Candida species being the most likely culprit. In his review of focal vulvitis (Peckham 
et al 1985) Candida was isolated in 67% of the cohort. There was no evidence of 
gonorrhoea, chlamydia or herpes simplex infection in any of the samples. 9% of the 
cohort had evidence of non-specific urethritis. Half of the group cultured positive for 
ureaplasma, however this is comparable with the rate found in normal healthy women 
and is probably not significant.
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The focus remained on Candida and the theory was proposed that in some patients 
the antigens of Candida albicans are cross reactive with certain vulvovaginal tissue 
antigens. They suggested that eventually an effective immune response against 
Candida albicans is aborted. This leads to a local inflammatory “response against 
se lf’ after repeated infections, which may be triggered by hormonal influences or 
stress (Ashman and Ott 1989).
We now know that although the majority of patients with VVS claim to have recurrent 
Candida over the years this probably just reflects the high rate of misdiagnosis in this 
condition and is not the cause. Therefore this theory does not seem likely.
Two studies in the same year did not find a higher rate of infective agents although it 
was proposed that recurrent bacterial vaginosis could contribute to symptoms as 
alkaline pH can be as irritant as acidic pH (Marinoff and Turner 1991).
The other study found that Group B streptococcus was the only infective agent to 
directly cause or worsen symptoms, although the prevalence was low (Goetsch 1991).
Two conflicting studies were then published, one quoting Candida albicans 
prevalence of 80% (Mann et al 1992) and the other a much lower rate of 8.8% (Bazin 
et a l l994).
The Canadian group took detailed microbiological swabs and again the presence of 
gonorrhoea, chlamydia, trichomonas and mycoplasma were not found. Bacterial 
vaginosis was present in 14% and ureaplasma in 17% of the cohort.
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With the exception of Candida species, the evidence is fairly conclusive that there is 
no link between bacterial or fungal agents and VVS.
It is unlikely that Candida is the cause of VVS, as most patients have been repeatedly 
tested and treated, even with negative results, for yeast infection prior to presentation 
in a specialist clinic, with no effect on their symptoms.
However it may be possible that fungal infection may act as a precipitating event to 
start the pathological process of VVS.
H o rm o n a l fa c to rs
Little attention has been paid to the role of hormones in W S . Several studies have 
alluded to possible links with situations affecting hormonal status, such as pregnancy 
and contraception, but no published work has concentrated on this aspect.
Goetsch (1991) stated 21 % of her cohort of patients developed symptoms post 
partum, although the possibility that W S  was related to perineal trauma at childbirth 
cannot be supported, as she had a greater proportion of nulliparous than multiparous 
women in her cohort.
Another study suggested that post partum W S  was secondary to the hypo- 
oestrogenised state of lactation, but specific comment was not made as to the 
proportion of women who had delivered who were breastfeeding. It was also 
proposed that sexual dysfunction could be due to fatigue or fear of dyspareunia 
(Schover et al 1992). However, women with post partum W S  had symptoms that
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continued for many years, even once they had stopped lactating and the hormonal 
balance had been restored. The authors also noted that in their cohort many women 
reported exacerbations of pain in the luteal phase of the cycle and during 
menstruation, and suggested that perhaps this was an indicator of a hormonal effect 
on the condition.
Only two studies have specifically postulated a role for oestrogen in the 
pathophysiology of VVS and these were concluded from information on contraception, 
specifically the oral contraceptive pill (OCP).
Bazin et al (1994) found that women who had ever taken the OCP had a relative risk 
of developing VVS of 5.8 (95% confidence interval 0.7-47.0) when compared to a 
control population. Those who were currently using the OCP as contraception had a 
relative risk of 6.8 (95% confidence interval 0.8-55.6) and those who had used the 
OCP early in life, i.e. below the age of 17 had a relative risk of developing VVS of 11 
(95% confidence interval 1.3-97.1). Length of use did not appear to be a determining 
factor.
They also found that an early menarche nearly doubled the risk of developing VVS, 
and increasing parity decreased the risk. From this they concluded that factors 
affecting the condition could be hormonal, and events occurring early in the woman’s 
reproductive life are important determinants of her developing W S . They proposed a 
possible mechanism as alterations in mucus, which has an irritant effect. It is known 
that oral contraceptives have an effect on glandular components and mucus secretion
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and this study argued that this could offer an explanation for the apparent connection 
with the OCP.
The other study to look at OCP, performed in Sweden, claimed that the argument 
proposed by the Canadian study, is contradictory, as a recognised treatment is 
vestibulectomy where the mucus producing glands are removed and the patient 
improves.
Their data found no difference in the parity of VVS patients compared with controls, 
but found the VVS patients had used the OCP for a significantly longer period of time 
(Sjoberg et al 1997). The same group had previously shown that OCP downregulates 
oestrogen receptors (Sjoberg et al 1989).
Their suggested mechanism was that if the OCP was started early, or used for a long 
period of time then the oestrogen receptors would become downregulated in the 
vestibule, which would lead to the epithelium becoming thin and fragile.
For those women with W S  not on the OCP, they suggested that even without the 
OCP they may have few oestrogen receptors, leading to a thin epithelium which is 
irritated by the acidic vaginal environment.
In a presentation to the ISSVD in 1999 Willems presented results of medical treatment 
and found good response to topical oestrogen cream, but no mechanism for action 
was proposed.
Many of the above authors have recommended that further work be done specifically 
on possible links between hormonal status and W S .
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P s y c h o lo g ic a l fa c to rs
Patients with vulval pain are often labelled as having a psychosomatic disorder, 
although often this is more likely to be due to the ignorance of the clinician than the 
underlying disease process. Certainly one route of referral to a specialist vulval clinic 
is via a psychosexual counsellor. Certainly psychological factors play a role in vulval 
disease but it is not obvious whether these problems are a result of the vulval pain or 
a cause of it.
In VVS there are identifiable physical features and therefore the latter is unlikely.
Studies looking at vulval pain in general found that vulvodynia patients are more 
psychologically distressed compared with women with other vulval pathologies. 
Essential vulvodynia causes more distress than vulval pain of an identifiable physical 
cause (Stewart et al 1994).
Factors as to why this is the case are inconclusive. Suggestion has been made that 
trauma could play a role in the development of vulval pain but no difference was found 
in the incidence of childhood physical or sexual abuse in women with vulvodynia 
compared to women with vulval symptoms from known pathology (Edwards et al 
1997).
Relatively few studies have specifically looked in detail at the psychology of patients 
with W S . In the first publication to address this problem, Schover et al (1992) found 
51 % of their cohort complained of other non genital pain syndromes. They also found
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a depression rate of 36% and somatisation of 42%. In their group, vulval pain 
occurred during periods of stress and this led to other problems such as vaginismus. 
They presented the hypothesis of a complex interactive process that women are 
vulnerable physiologically due to an unknown local or genetic factor, and vulnerable 
psychologically if they tend to react to stress with somatic symptoms, especially 
chronic pain. This leads to decreased sexual desire and arousal, which may 
contribute to a degree of vaginismus. Further episodes of repeated trauma of coitus in 
an unaroused state then leads to vulval inflammation and further psychological 
distress.
Another study linked W S  to increased somatisation and shyness (van Lankveld et al 
1996). They found no difference in psychological distress, marital dissatisfaction or 
risk of psychopathology compared to a control population.
This was the only study that analysed the behaviour of the partners of women with 
W S . They concluded that both the women with W S  and their partners were 
psychologically healthy, although W S  may be associated with a “situationally defined 
sexual dysfunction” for the woman. This was due to the fact that the women had 
increased problems with arousal when their partners were present but less problems 
with masturbation than the control population. This is understandable given the 
stresses that sexual dysfunction of any sort places on a relationship.
Their final conclusion was that W S  is part of a circular process in which physical 
condition and sexual dysfunction interact.
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Parallelism between W S  and somatisation disorders has been suggested (Jantos and 
White 1997). They highlighted the psychogenic problems brought about by 
"symptoms not caused by organic factors”. They made a comparison with 
premenstrual syndrome, of which they reported a prevalence of 85% in their cohort of 
women with VVS. Stressing the lack of organic factors the authors suggested that it 
is, by default, a psychogenic problem. This study emphasised that the persistence of 
pain will have a debilitating effect on the patients' psychological well being.
Chronic pain is frequently associated with depression and estimation of the 
prevalence of mood disorder in chronic pain patients varies considerably, reflecting 
both the short-comings of the measures and diagnostic procedures used, and 
variations in the populations studied.
The authors illustrated this by showing that the cohort self reported a depression rate 
of 69%, but using the Beck Depression Inventory they classified 91% as having 
moderate to severe depression and 57% having expressed suicidal ideation or intent. 
However it was not possible to exclude the premenstrual syndrome component of 
depression from W S  patients. They did not find any evidence of phobic or 
hypochondriacal behaviour.
It is very easy to classify the difficult patient as mad, especially when solid physical 
features are difficult to find. It is not surprising, given the length of duration of most 
women’s symptoms in W S , that they become obsessed with their problems, 
considering the enormous impact that this condition has on their relationships and 
lifestyles. Certainly there is a psychological component to W S  but this is more likely
53
to be a sequelae of the frustration brought about by the lack of diagnosis or successful 
treatment. Sometimes purely agreeing that there is a physical problem is enough to 
stop these women questioning their sanity.
O th e r  a e t io lo a ic a l fa c to rs
Several other possibilities have been suggested, the two most commonly quoted are 
the relationship between VVS and diet and that with interstitial cystitis.
A case report first suggested that there was a link with oxalate and VVS, in which a 
patient was presented with fluctuating hyperoxaluria and increased urinary pH. The 
authors hypothesised that oxalate crystals excreted in the urine are irritant to the 
vulval epithelium and could give rise to the physical findings. The patient was treated 
with calcium citrate and a low oxalate diet and she improved (Solomons et al 1991).
This was an isolated case and further studies have not supported this evidence.
Poole and Munday (1999) investigated 31 patients with VVS for abnormal oxalate 
intake or excretion. None of these women were found to have increased levels of 
urinary oxalate. One third of the cohort improved with a low oxalate diet without 
calcium citrate but they could find no evidence to suggest that it was the reduction of 
oxalate content that altered symptoms.
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A further study also showed that there was no difference in the 24 hour excretion of 
oxalate between women with VVS and healthy controls, in which the authors 
concluded that although urinary oxalate may be a non-specific irritant that aggravates 
vulvodynia, its role as an instigator is doubtful (Baggish et al 1997).
A link between interstitial cystitis and focal vulvitis was first proposed in 1990. 
(McCormack) This was reiterated as a link between W S  and interstitial cystitis based 
on the evidence that both the vestibule and the bladder are of urogenital sinus origin. 
(Fitzpatrick et al 1993) Neither condition has specific histopathological features and 
non-specific inflammation and immunoglobulin deposition are common to both. The 
subtle differences in pathological findings are explained by the different architectures 
of the two structures. The authors suggested that there was a psychological 
component to both conditions and raised the possibility of an allergic factor that may 
increase the epithelial permeability to allergens. The authors presented three patients 
with concurrent W S  and interstitial cystitis and suggested that this may be a 
generalised disorder of urogenital sinus derived epithelium.
A later study tried to show parallel pathologies between the two conditions (Stewart 
and Berger 1997). It is known that interstitial cystitis shows epithelial defects and 
absent or greatly decreased mucous layer and decreased acid mucopolysaccharide 
content when stained with periodic acid - Schiff/colloidal iron staining with van Gieson 
counterstaining and immunofluoresence (Gillespie et al 1990). In addition both 
conditions are associated with increased angiogenesis, which is visible in the 
vestibule, and at cystoscopic examination of bladder mucosa.
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A later paper by the same author suggested that abnormal arylakylamine metabolism 
in interstitial cystitis produces pathological changes via both blood and urine. This 
ischaemia, together with abnormal urinary metabolites, result in the loss of the 
protective mucous membrane in the bladder, allowing urine to contact exposed nerves 
and therefore causing pain (Gillespie 1993).
Stewart and Berger (1997) hypothesised that a similar process affected the vulval 
epithelium in VVS. However their results showed no defects in the epithelium of VVS 
patients, although there was some complement deposition along the dermo-epithelial 
junction, and perivascular IgM. They recommended further investigation into the 
possible role of complement in these two conditions.
A further investigation was performed to examine the inter-relationship between VVS 
and urethral syndrome by looking at urethral pressure variability (Foster et al 1993). 
They found that W S  was associated with an increase in urethral pressure variability 
compared to both patients with chronic pelvic pain and normal controls. The probable 
source of this was the variation in the muscle tone of the urethra. Unfortunately the 
relationship between this finding and the pathogenesis of W S  is unknown.
M o le c u la r  fa c to rs
When the hypothesis of this thesis was developed, little work had been published 
investigating W S  at a molecular level. However, during the last few years, 
researchers have investigated possibilities to understand the mechanisms behind 
vestibular pain.
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In 1996, Masterson et al assessed Natural Killer (NK) cell activity in patients with VVS, 
as a first step in assessing the immune system in these women. They found that 
women with VVS had decreased NK cell activity compared to healthy controls, 
although statistical significance was not achieved due to small numbers.
They suggested that as NK cells are important in several immunomodulatory 
mechanisms, including tumour surveillance, control of viral infection and secretion of 
cytokines, and that some forms of VVS may be associated with Human Papilloma 
Virus (HPV) infection, that this was the link that may explain the decrease in NK cell 
activity. Unfortunately the HPV status of their patients was not evaluated, and indeed 
the role of HPV infection in W S  as a main aetiological factor remains unlikely.
Abnormal neurology of the vestibule has been considered to explain the hyperalgesia. 
A theory of vulvodynia as primarily a pain disorder secondary to the establishment of a 
sympathetically maintained pain loop has been suggested. (Cox 1995) This may 
occur with chronic irritation of any area rich in sensory nerves.
Inflammatory mediators, released by injury or inflammation, activate the unmyelinated 
C fibre nociceptors and prolonged firing of these nerves sensitise wide dynamic 
neurones in the dorsal horn. These neurones then respond abnormally to input from 
mechanoreceptors, and so touch is perceived as pain (allodynia).
Neuroendocrine cell-axonal complexes have been identified in the minor vestibular 
glands (Warner et al 1996). The authors also demonstrated substance P, a known 
vasodilator and mediator of neurogenic inflammation, in the axons. They proposed 
that these findings may explain the exquisite tenderness found in W S . Increased
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number of substance P fibres had previously been found in the bladder mucosa of 
women with interstitial cystitis (Pang et al 1995).
A later study evaluated nerve fibre density in women with VVS (Westrom et al 1998). 
Forty-seven patients were assessed and compared to 6 controls, 4 being post mortem 
samples. They found increased nerve fibre proliferation in the samples from women 
with VVS and suggested this would provide a morphological basis for enhanced 
neuronal firing, as suggested in the pain loop theory. Again the comparison was 
made with interstitial cystitis, where similar results were found (Christmas et al 1990). 
These findings have been confirmed by Bohm-Starke et al (1998), who showed a 
significant increase in intraepithelial innervation in women with VVS, suggesting focus 
should be on the change in the peripheral innervation as a possible explanation for the 
symptoms of VVS. The authors assumed these free nerve endings were nociceptors, 
transmitting noxious stimuli, resulting in pain. This assumption was later proved 
correct when the nerve fibres were neurochemically characterised. (Bohm-Starke et al 
1999) They proposed that the crucial question seems to be whether the increase in 
sensory nerve activity is related to inflammation of the mucosa in women with VVS. 
Immunohistochemical analysis of the neuroendocrine cells of the minor vestibular 
glands found the degree of inflammation in vestibular tissue in women with and 
without W S  was not significantly different (Sloane et al 1998). The authors confirmed 
the presence of neuroendocrine cells in the minor vestibular glands and that the 
number of cells expressing the inflammatory mediator serotonin and the chemokine 
receptor CXCR2 was upregulated by inflammation.
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Little work has still been done looking at inflammatory markers in W S . Foster and 
Hasday (1997) investigated tissue levels of Interleukin 1 p (IL ip ) and Tumour 
Necrosis Factor a (TNFa) and found elevated concentrations in women with W S , 
although paradoxically levels were lowest in the vestibule, the area of highest 
hyperalgesia. Unexpected findings were recently published showing low expression 
of inflammatory markers cyclooxygenase and inducible nitric oxide synthase in women 
with W S  and controls (Bohm-Starke et al 2001). These results indicated there was 
no active inflammation present in W S .
This subject will be discussed in greater detail in chapter four.
Genetic investigation appears to have been limited to a single publication. Jeremias et 
al (2000) examined the relationship between W S  and polymorphisms in the gene 
coding for IL-1 receptor antagonist (IL-1RA), which is a naturally occurring down- 
regulator of the proinflammatory response. They found a significant increase in the 
homozygous form of allele 2 of the gene encoding the IL 1 receptor antagonist. 
Apparently IL-1 RA functions to down regulate IL 1 activity, but in allele 2 positive 
individuals IL-1 and IL-1RA are upregulated. This results in a net increase in IL-1 
bioactivity. When this occurs in women with autoimmune diseases, the inflammatory 
related symptoms are more severe than in women with the same disease but who lack 
the IL-1 RA 2 allele. The authors suggest this evidence indicates there is a genetic 
component to W S , although it is uncertain whether the allele is related to increased 
susceptibility to development of the syndrome or to the severity of the symptoms, or to 
both.
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In conclusion, the aetiology of VVS still remains a mystery. We can be fairly certain 
that it is not an infective process and that any possible inflammation is caused by an, 
as yet unidentified factor. These possibilities raise interesting questions and certain 
areas remain largely unexplored, in particular the role of hormones in the vestibular 
area, and whether W S  is indeed an inflammatory condition, both of which warrant 
further investigation.
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Treatment of vulval vestibulitis syndrome
M e d ic a l T re a tm e n t
It is common for women to have tried a wide variety of treatments prior to attendance 
to a specialist clinic. Simple measures should always be tried at first but unfortunately 
are not usually successful. 1
Early in the history of a VVS an uncontrolled study was published to look at the 
possible effect of five unrelated drugs, Isotretoin, Dapsone, Aciclovir, Progesterone 
and Capsaicin (Friedrich 1988).
Isotretoin was used in 7 patients, none of whom showed any benefit whilst on the 
treatment but improved 3 months after cessation of the drug. Unfortunately this drug 
has major side effects and from this it cannot be concluded whether the effect was 
due to a delayed effect or whether the patients would have gone into spontaneous 
remission without treatment.
Dapsone was used in 14 patients but is complicated in that its use needs regular 
monitoring due to the possible side effect of anaemia. Two patients appeared cured 
following the treatment, but the majority remained unchanged and one patient's 
symptoms worsened.
Aciclovir was used in 15 patients: 7 reported a reduction in the severity of their pain 
and 2 were cured. 5 remained unchanged and 1 patient worsened.
There was no correlation between the response, nor degree of response and the 
presence of herpes simplex virus antibodies or level of titre.
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Progesterone was unhelpful and the majority of the patients experienced vulval 
burning secondary to application of the cream.
Capsaicin produced severe burning with each application, requiring the use of oral 
narcotics and no response was reported in half of the cohort. Two patients were cured 
and 1 showed moderate improvement. The author suggested that W S  represents a 
form of localised neuropathy, similar to that seen in varicella infection. This argument
i
was based on the fact that aciclovir and capsaicin are effective in treatment of 
varicella neuropathy, and appeared to have some beneficial effects in VVS.
VVS as a neuropathy was the rationale behind the use of tricyclic antidepressants. 
Using a similar regime to that used in dysaesthetic vulvodynia 60% had a positive 
response (Pagano 1999).
More recently studies have concentrated on a variety of treatments but unfortunately 
most of the published work is uncontrolled and there is a lack of randomised trials 
comparing different treatments.
In one study simple measures produced a poor or absent response in the majority of 
patients, and in the same study, topical steroids only had a moderate or good 
response in less than 20% of the cohort (Munday and Byrne 1996).
Lubricants (McKay 1985), topical anaesthetics (Turner 1992) antibiotics and steroids 
appear ineffective in the literature but there have not been any controlled clinical trials 
(Bergeron et al 1997).
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Sonnex (1996) reported treatment with topical steroids, antifungals and intralesional 
triamcinolone. In his series there was no response to antifungals and again 20% 
responded to topical potent steroid or intralesional injection of triamcinolone. Three 
groups were identified depending on the severity of erythema, and unfortunately were 
not treated with a standard regime. The group who had more severe erythema were 
pretreated with anti fungals. The groups were too small to show any significant 
difference between the treatments.
One clinical trial looked at treatment response to topical ketoconazole (Morrison et al 
1996). Thirty-four patients were treated with 2% ketoconazole cream three times a 
day and 44% of their cohort showed an improvement over 8 months. The authors 
were unsure as to the mechanism by which ketoconazole cream had produced the 
response, and whether the patients were tested for fungal infection is not mentioned. 
Although the action is assumed to be anti fungal, ketoconazole does in fact have an 
anti inflammatory action equivalent to 1% hydrocortisone. It blocks lipoxygenase and 
inhibits production of leukotrienes and thromboxanes. They also reiterated the power 
of the placebo effect and recommended that a double blind controlled trial was 
needed.
The use of interferon is first line medical treatment in some centres.
Interferon is a cytokine that prevents viral replication by inducing production of 
intracellular antiviral enzymes and enhancing the activity of natural killer cells against
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virus infected cells. Alpha, beta and gamma interferon is available, but beta interferon 
reportedly has the lowest rate of systemic side effects.
The possible association between W S  and HPV infection encouraged the local 
application of interferon. The injections were given into the vestibule 3 times per week 
on 12 occasions, but caused intense pain when introduced and so was discontinued in 
a large majority of patients. In the ones that persisted with the treatment 15 out of 16 
reported relief. All these patients were HPV positive. Interferon was ineffective in 
patients where HPV was not identified (Horowitz 1989).
A case report was published using interferon by an intramuscular route. The patient 
was cured and there were reduced side effects compared with local administration 
(Bornstein et al 1991). This was followed up by a series of 7 women of which 4 
gained complete remission, 2 did not respond and 1 had recurrence of symptoms after 
treatment (Bornstein et al 1993).
A larger series of 55 women was published using intralesional alpha interferon in both 
HPV positive and negative patients. Just under half reported partial or substantial 
improvement, but these were all HPV positive women. The author concluded, using a 
cost analysis, that intralesional alpha interferon treatment as first choice in 
management of idiopathic W S , is a cost effective strategy (Marinoff et al 1993).
These accounts do not allow for the varying reports in the literature of the prevalence 
of HPV infection. Given that many studies have not found an association between 
HPV and W S  it is difficult to suggest that interferon will be beneficial to many.
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One study has been published using methylprednisolone and lidocaine injections to 
treat VVS (Murina et al 2001). Decreasing doses of both drugs were injected into the 
vestibule at weekly intervals, for three weeks. A 68% response rate was reported.
The method of administration was similar to that used in intralesional interferon 
injections. The authors suggested this was an effective treatment as 
methylprednisolone has immunomodulatory and anti-inflammatory properties with 
lasting efficacy against the chronic inflammation of W S . They also proposed that 
lidocaine not only acts as an anaesthetic but also exerts direct action on the vestibular 
nerve fibres involved in the pathogenesis of the syndrome. Therefore, unfortunately it 
is difficult to know which treatment is the effective component.
Other less invasive approaches have been suggested, including acupuncture (Secor 
and Ferrita 1992, Powell and Wojnarowska 1999).
Two studies have been published suggesting that electromyographic biofeedback of 
pelvic floor musculature is beneficial (Glazer et al 1995, McKay et al 2001).
The first study reported an increase of pelvic floor muscle contraction of 95% with a 
decrease in resting tension. Instability of muscles at rest was also reduced and 
subjects reported a decrease in pain of 83% sufficient that 22 out of 28 could resume 
sexual intercourse. They believed that cutaneous vulval disturbances destabilised 
pelvic floor musculature and suggested that whatever the initial insult or aetiological 
factor, vulval vestibulitis syndrome may be a result of autonomically mediated pain.
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They concluded that this mechanism as a final common pathway for multiple 
pathologies and multiple aetiologies, and may explain the lack of consensus on a 
single antecedant despite consistency in symptomatology of the syndrome.
The second study reported a similar improvement rate of 85% and proposed that 
treatment to restabilise the pelvic floor muscles has significantly less morbidity than 
other treatments and the approach is cost effective.
S u rg ic a l T re a tm e n t
Despite attempts to find a non-invasive, effective solution, surgery still remains the 
treatment of choice in selected patients with VVS, although success rates vary in 
published results.
Perineoplasty was initially described as treatment for dyspareunia caused by vaginal 
outlet distortion (Woodruff et al 1981).
The same author then applied this principle to vulval vestibulitis syndrome patients 
(Woodruff and Parmley 1983). They described a perineoplasty to include the hymenal 
ring and 0.5cm of tissue adjacent to this. The incision extends from below the urethra 
to the fourchette internally, and the lateral incision extends down and terminates 
above the anal orifice. This includes the fourchette and sometimes the labia minora. 
The vagina is undermined and exteriorised to be sutured to the skin.
In this series all patients experienced major symptom relief.
Using the same surgical technique, the Woodruff perineoplasty, the study was 
repeated 5 years later and 13 of 22 patients were much improved. The remainder 
experienced no relief (Reid et al 1988).
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In his initial description of vulval vestibulitis syndrome Friedrich (1987) used excision 
of the vestibule and vaginal advancement. He excised the hymen and all sensitive 
areas of the vestibule. Areas anterior to the urethral meatus were excised and left to 
heal by secondary intention. 56% of the cohort was cured, or reported to be much 
better.
Marinoff and Turner (1991) suggested that the entire vestibule needed to be removed. 
They had stricter criteria for entry to surgical procedure and performed a modified 
Woodruff's perineoplasty, where the outer incision for the paraurethral glands was 
along Hart's line including the fourchette. Inner incision was behind the hymenal ring. 
They excised a horseshoe of tissue and mobilised the vaginal mucosa and advanced 
it to cover the defect. Reported complications were wound haematoma, partial or 
complete dehiscence of the wound, uneven healing and Bartholin's duct stenosis and 
subsequent cyst formation.
Vestibuloplasty, during which the tissue is undermined but not excised, was suggested 
as an alternative approach. However in a study comparing the two procedures no 
relief was found with vestibuloplasty, whereas 9 out of 11 patients were cured with 
perineoplasty (Bornstein et al 1995). He speculated the reason of failure of 
vestibuloplasty as reinnervation following denervation and subsequent 
hypersensitivity. It was suggested that given denervation did not improve symptoms
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initially that innervation disturbances are not a direct cause of W S . He concluded that 
vestibuloplasty is not an acceptable procedure for treatment of VVS.
Attempts have been made to simplify the surgery.
One study suggested that limits of excision should be the areas where tenderness 
was elicited. Success rates of 75% were reported and procedures varied from 
posterior hymenectomy to posterior vestibulectomy and removal of the paraurethral 
areas (Goetsch 1996).
A modified vestibulectomy was presented where the superior excision margins were 
limited to halfway up the inner aspect of the labia minora with or without a modified 
Fentons procedure. 59% had a complete response, 30% had a partial response and 
11% had no response (Kehoe and Luesley 1996). Although proposed as an 
alternative, the success rate is lower than that of full vestibulectomy and no 
information is given about long term follow up and recurrence rates.
The use of the LASER has been suggested as treatment for vulval vestibulitis 
syndrome: Laser vulvectomy for vulval vestibulitis syndrome was reported to have 
inconsistent results but improvement was shown in up to 60% (Davis 1989).
A small series was presented where laser ablation of the vestibule was performed. 
These women were slow to heal, many taking many months (Kaufman and Friedrich 
1985). The most detailed account of laser surgery used laser ablation of the inflamed 
areas. In patients with tenderness over the duct areas only, laser produced a good
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result. If tenderness extended further than the ducts laser did not produce a 
significant improvement (Michelwitz et al 1989). Patients who underwent 
perineoplasty had an elliptical specimen excised, encompassing the area between the 
hymenal ring and the perineal body ridge and extending to both Bartholins ducts. All 
of these patients improved.
Treatment protocols remain substandard, with surgery still being the only option in 
women who do not respond to medical treatment.
A recent review of non surgical treatment suggested tricyclic antidepressants as first 
line treatment with biofeedback and psychological counselling, with non responders 
proceeding to surgery. This review reiterated the need for randomised multicentric 
clinical trials (Mariani 2002).
The lack of randomised trials was commented upon by Bergeron et al (2001) when 
they performed a randomised trial of vestibulectomy, electromyomgraphic biofeedback 
and group cognitive-behavioural therapy.
In this study 78 women of the original 87 completed the study as 7 assigned to 
vestibulectomy dropped out before treatment, as did 1 each assigned to biofeedback 
and behavioural therapy. The authors argue that this may influence their findings: that 
vestibulectomy was significantly more successful than other groups, although all three 
groups improved with treatment. However, they also performed a posteriori intent-to- 
treat analysis to account for the pre-treatment drop outs, but found that the general 
pattern of results was confirmed.
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They concluded that “multimodal treatment approaches may be essential to achieve 
significant improvement in all aspects of the disorder and that cognitive behavioural 
therapy and biofeedback represent promising alternatives to vestibulectomy”.
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Objectives of thesis
VVS continues to pose challenges. At present our diagnosis, assessment and 
evaluation of response to treatment is subjective. Our choice of treatment is 
universally random, as we are unsure about the underlying pathological process we 
are treating.
From the literature, basic questions have been raised as to the nature of this 
syndrome. It has always been assumed that VVS is a chronic inflammatory condition 
but anti-inflammatory treatment has been unsuccessful. Other perspectives, such as 
possible roles of hormonal components have not yet been investigated.
Until our understanding of the aetiology of the complex condition improves we are 
unlikely to be able to improve our standard of care for these women.
In view of these problems, the objectives of this thesis are:
1. To define the epidemiological characteristics of a selected cohort of patients 
and compare these to existing data, i.e Are there patterns or characteristics that 
further define W S  patients and their responses?
2. To objectively quantify the pain experienced in VVS. i.e. Is the use of an 
“algesiometer” valuable in assessing and following patients with VVS?
3. To explore whether W S  is an inflammatory condition, i.e. What is the 
expression of inflammatory cytokines in tissue of patients with W S ?
4. To explore whether W S  has a hormonal component, i.e. What are the 
oestrogen levels of patients with W S , and are there altered expression of 
oestrogen receptors in tissue of these patients?
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CHAPTER TWO - ASSESSMENT OF VULVAL VESTIBULITIS 
SYNDROME
Diagnosis and assessment of vulval disease is often considered to be a difficult area 
of general gynaecology. Frequently the diagnosis is apparent if a detailed history has 
been taken, but often women do not volunteer relevant information, particularly that of 
a sexual nature, and may need to be prompted by the clinician. Women may not have 
presented for many years due to fear or embarrassment, and it is important to build a 
good rapport quickly.
In a Vulval Clinic, women may arrive with cynical views as many have had 
misdiagnosed symptoms for years and will have seen multiple clinicians.
A sympathetic and comfortable environment for taking a history and examination is 
essential.
Assessment of W S  is particularly difficult as physical signs are often minimal, or the 
condition is sufficiently severe that patients are unable to tolerate examination. 
Patients with W S  will often give the diagnosis in their history. The classic story is of a 
young woman in her twenties or thirties who has had normal sexual relationships in 
the past. She then describes sudden onset of superficial dyspareunia, often without 
identifying a precipitating factor, but often blaming candidal infection. The pain is 
sharp and precipitated by attempted penetration at intercourse, but then often leads 
on to a chronic vulval burning that may last hours or days. Frequently the pain is so 
severe as to prevent intercourse completely. When questioned these women also 
report difficulty in tampon use and have changed to sole use of sanitary towels.
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With the diagnosis of VVS in mind it is important to examine the patient, to exclude 
other causes of vulval pain and to confirm the physical findings of W S .
Examination of the vulva
The optimal situation in which to confirm the diagnosis of VVS is a specialised Vulval 
Clinic, ideally staffed with a dedicated nurse, which provides a private examination 
room, and not just a curtain pulled round in the corner of the gynaecology clinic.
In our Vulval Clinic we have an examination couch that tilts back to 90 degrees placing 
the patient into the lithotomy position. It is essential to have good lighting and the 
vulva should be examined both with the naked eye under a bright directional lamp and 
with use of the colposcope.
Use of the colposcope in vulval disease is becoming more common and enables a 
magnified view of the vulva which makes subtle changes more obvious and allows 
more accurately directed biopsy if needed.
Our colposcope is connected to closed circuit television, which allows the patient to 
see the area being examined and enables her to point out any areas that are 
symptomatic.
Although, as previously described in the introduction to this thesis, acetic acid and 
toluidine blue stains are useful in identification of abnormal areas in other forms of 
vulval disease; they do not have a role in the diagnosis and assessment of VVS.
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In VVS there may be minimal physical signs, the changes that do appear are confined 
to the vestibule with no abnormality elsewhere on the vulval skin. This explains why 
VVS is often misdiagnosed, as even in a gynaecology clinic it is difficult to adequately 
view this area and the abnormalities seen are often subtle.
The usual findings in a patient with W S  are erythema of varying degrees within the 
vestibule and apparent enlargement of the openings of the greater and lesser 
vestibular glands.
Occasionally it is necessary to biopsy the vestibule, to exclude other vulval pathology 
or for research purposes. This is performed in the Vulval Clinic using the same 
technique for other areas of the vulva (MacLean and Reid 1995).
Local anaesthetic, usually 3% Citanest (prilocaine 30mg/ml) plus Octapressin 
(felypressin 0.03iu/ml) contained within a 2.2ml cartridge is injected, by use of a dental 
syringe using a 27-gauge needle into the area to be biopsied.
This is a quick acting agent and the biopsy is then taken using a 4mm Stiefl punch 
biopsy. The core of tissue is then removed and the haemostasis achieved at the base 
of the wound by application of silver nitrate sticks or Monsel's solution (Ferric 
subsulphate).
W S  is a chronic condition, usually with symptoms persisting for more than six 
months, with many patients reporting symptoms lasting many years. However, an 
allergic reaction, or an infective agent can cause an acute vestibulitis. Therefore in 
the assessment of a patient with possible W S  these factors need to be excluded.
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In our clinic all patients with a history indicative of W S  will have a complete set of 
swabs taken at initial assessment: vaginal and endocervical swabs are collected for 
trichomonas, gonorrhoea, yeast and chlamydia infection. These are sent for 
laboratory analysis. Bacterial vaginosis can be tested for in the clinic by application of 
10% potassium hydroxide solution to a vaginal swab and smelling for the presence of 
amines. Unfortunately patients with severe vestibulitis may not be able to tolerate a 
speculum examination, in which case low vaginal swabs are taken, as well as urethral 
swabs for chlamydia.
Assessment of vestibular tenderness
One sign that is always easily elicited in patients with W S  is tenderness over the 
entrance to the vestibular glands. Traditionally the method of eliciting and assessing 
tenderness was by use of a cotton tip. Goetsch (1991) suggested rolling a Q tip over 
the entrance to the vestibular glands to provoke the pain described with attempted 
penetration. This is shown in Fig 2.1.
There are many problems associated with this method. It gives the clinician the 
answer to the question of whether or not tenderness is present, but is subjective and 
does not quantify the tenderness elicited. Equally, it is not a reproducible method of 
assessment as it is completely operator dependent. Different clinicians will apply 
different pressure and even the same clinician is unlikely to be able to reproduce the 
same level of force over different vestibular areas, let alone at subsequent clinic visits.
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Fig 2.1 Q tip application
This method is not recordable, except as pain being present or absent, and therefore 
subtle response to treatment is difficult to ascertain as the clinician is relying on the 
patient’s memory of previous visits.
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A la e s io m e tr v
To overcome these problems the vulval algesiometer was developed by the 
Departments of Genito-Urinary Medicine and Biomechanical Engineering in Freedom 
Fields Hospital in Plymouth.
The algesiometer consists of a hand held probe that includes a metal thrust probe 
contained within a plastic-casing sleeve. (Fig 2.2)
Fig 2.2 The algesiometer
The sleeve serves a dual purpose: flattening the skin surrounding the vestibular gland 
and therefore enabling accurate aim over the entrance to the gland itself, and 
secondly when pushed back it activates the sensor which causes the thrust probe to 
fire. The hand held probe is connected to a main control unit that is powered by mains
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electricity. The control unit allows the force of impact and the frequency of firing of the 
thrust probe to be altered.
The force readings on the algesiometer correspond to pre-set levels of force 
measured in milli Newtons and the machine has been calibrated accordingly. The 
control unit it connected to a foot pedal that allows the force to be increased whilst 
examining the patient.
The LCD circuit used gives a reading of 0 a finite value in milli Newtons. Therefore for 
statistical analysis all readings are increased by 1. The force value for each reading in 
shown in the table 2.1. If the patient does not feel discomfort with a force reading of 7 
then she is said to have scored a maximum of 8 for that area.
Table 2.1 Force settings for the algesiometer
Force setting Measured 
force (mN)
0 178
1 356
2 578
3 756
4 1068
5 1334
6 1646
7 2046
The initial work using the algesiometer, published in 1996 showed that patients with 
W S  achieved lower readings than a normal control population (Curnow et al 1996).
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The lower readings corresponded to decreased force exerted by the algesiometer. 
Therefore the more tender the vestibular area the less force could be tolerated.
Further work showed assessment of the vestibule within the condition when treated 
with ketoconazole. That study looked at the improvement of the algesiometer 
readings during treatment with ketoconazole, but did not comment on the patients' 
symptomatology (Morrison et al 1996).
In view of these factors we decided to look at the algesiometer readings of women 
before and after treatment, to see whether it correlated with the patients' subjective 
view of symptom severity.
Study
In the group of women who had improved with treatment, we wanted to see whether 
the algesiometer readings would correlate with the improvement in patients’ 
symptoms.
Improvement was defined as the point at which the patient was no longer symptomatic 
and able to tolerate penetrative intercourse.
Before participating in this study all patients had a full set of swabs taken to exclude 
chlamydia, gonorrhoea, Candida, trichomonas and bacterial vaginosis.
All patients had been examined to exclude other vulval pathologies.
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M e th o d
Fifty-five patients attending the Vulval Clinic with a diagnosis of W S  of more than six 
months duration were assessed using the algesiometer.
Of this group 9 patients only had an initial assessment reading taken. Thirty patients 
had sequential readings before and after treatment and of these 25 reached the point 
of discharge from the study. Eleven patients only had a single reading after treatment 
and 5 had sequential readings after different treatments but no initial assessment.
This was due to different referral patterns and was dependent on treatment used prior 
to the Vulval Clinic visit.
The treatment protocol followed in this clinic was 2 months topical application of 
Trimovate® cream, followed by 2 months topical application of Premarin® cream, if 
there had been no response to the initial treatment.
For the purpose of this study the thrust probe of the algesiometer was set at a 
frequency of 0.5 seconds, this meant that a single thrust of the probe was delivered 
over the selected vestibular area. This was thought to be more representative of the 
pressure applied during intercourse, rather than the continual tapping action that 
would be reproduced using a higher frequency of thrust.
Individual readings were recorded from the paraurethral glands and the two posterior 
vestibular glands (Morrison et al 1996). The sum of these readings gave a final score 
for that visit.
80
Each of the four vestibular areas were assessed in order, starting with the probe firing 
with minimum force and increasing the force by one reading at each application of the 
probe. The force was increased until the patient reported that the pain provoked was 
representative of that pain produced by coitus.
The readings for each area and the total for that visit were recorded on a vulval map, 
as shown in Fig 2.3.
Fig 2.3 Positions of algesiometer readings
Urethra
Posterior 
Vestibular glands
Para urethral 
glands
sum  of Paraurethral scores
Total score =
Sum  of Posterior Vestibular scores
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R e s u lts
Following treatment, the patients returning to clinic were reassessed using the 
algesiometer in the same way.
Table 2.2 shows the individual readings of the algesiometer probe for each of the four 
glands tested at each visit after different treatments.
KEY: 1 = Left paraurethral gland
2 = Right paraurethral gland
3 = Left posterior vestibular gland
4 = Right posterior vestibular gland 
T = Total of all 4 glands assessed
I = Initial visit 
a = First line treatment 
b = Second line treatment 
c = Third line treatment
- = Patient requested discharge as was symptomatically better but
had not achieved maximum scores
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Table 2.2 Algesiometer readings
Pt 11 21 31 41 TI la 2a 3a 4a Ta lb 2b 3b 4b Tb lc 2c 3c 4c Tc
DA 8 8 8 8 32
CB 8 8 7 5 28
LB 7 7 7 5 26 8 8 8 8 32
HB 4 4 3 3 14 8 8 6 6 28 8 8 8 8 32
MC 1 0 1 3 5 2 2 3 3 10
MC 0 0 0 0 0
DC 7 7 4 7 25 8 8 8 8 32
KD 5 5 5 5 20 8 8 8 8 32
JD 0 1 1 1 3 8 8 8 7 31 - - - - -
MD 8 8 8 8 32
MF 3 3 8 8 22 3 3 8 8 22
LF 2 3 4 2 11 8 8 8 8 32
VG 7 7 7 7 28 8 8 7 7 30
DG 3 3 2 3 11 7 7 5 5 24 7 7 5 4 23
SG 8 8 8 8 32
JH 8 8 7 7 30
EH 8 6 4 4 22 6 6 6 5 23
GH 3 7 2 1 13 8 8 8 8 32
VK 8 8 8 8 32
EL 7 7 4 3 21 7 7 7 7 28 - - - - -
EU 0 1 1 1 3 8 8 8 8 32
JL 3 3 3 3 12
KL 2 3 6 6 17 3 3 3 3 12 8 8 8 8 32
KL 3 4 1 2 10 4 4 3 3 14 4 4 3 3 14
AL 0 0 1 1 2
JL 6 7 5 7 25 8 8 8 8 32
VM 7 7 7 7 28
HM 8 8 3 7 26 8 8 8 8 32
AMG 8 7 7 7 29
CM 7 7 8 8 30
TM 7 7 1 2 17 8 8 8 8 32
CND 4 7 3 1 15
JN 4 7 5 6 22 8 8 7 8 31 8 8 8 8 32
JP 7 7 7 7 28 8 8 8 8 32
LP 7 7 5 5 24 7 7 7 7 28 8 8 8 8 32
SP 0 0 0 0 0 5 3 2 2 12
SR 8 8 8 8 32
SR 1 1 1 6 9 8 8 8 8 32
SR 3 2 3 2 10
LS 5 6 6 6 23 3 5 5 6 19 8 8 8 8 32
SS 7 7 7 7 28 8 8 8 8 32
LS 7 7 7 2 23
HS 7 7 2 7 23 32
JS 32
AT 0 0 0 0 0
AT 8 8 1 5 22 8 8 7 8 31
LT 7 5 7 5 24
AT 1 1 1 1 4 8 8 8 8 32
SV 7 7 5 7 26 8 8 8 8 32
JV 7 7 7 3 24 8 8 8 8 32
SW 0 1 1 1 3 3 5 8 8 24
- CW 3 3 3 1 10 8 8 7 7 30
TW 32
Tw 1 7 2 4 14 8 8 8 8 32
1GW 7 4 6 7 24 32
\
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In order to evaluate the correlation between subjective assessment by the patient and 
objective assessment by the algesiometer, we looked at the patients whose symptoms 
had improved sufficiently to be discharged from the clinic and analysed their 
algesiometer scores before and after treatment. This comprised a group of 25 
patients.
These results are shown in Fig 2.4.
Fig 2.4 Algesiometer readings before and after treatment
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Number of patients
The results show that there is correlation between algesiometer readings and the 
patients' subjective reports on the progress of their symptoms. Patients whose 
symptoms were initially bad had low algesiometer readings. Those who reported an 
improvement in their symptoms also had an improvement, i.e. rise in their 
algesiometer scores.
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There were patients who did not respond to treatment. Their mean pre treatment 
scores were 11 and mean post treatment scores were 18. These results have not 
been included in the chart. Response to treatment is discussed in a later chapter.
Individual scores of each of the areas were recorded to see if there was a difference 
between anterior paraurethral and posterior vestibular areas.
In the total group tested at their initial visit, symptoms were worse in the anterior 
glands in 4 patients and worse in the posterior glands in 11 patients. Twenty-four 
patients had no significant difference between scores of the anterior and posterior 
areas. The majority of patients were symptomatic in both sets of glands. Only 3 
reported no symptoms in the anterior areas and 2 had no symptoms in the posterior 
areas. This lack of pattern was also evident in the group of 25 who improved to the 
point of discharge. Of the 25 patients only 3 had worse anterior symptoms. Eleven 
patients had no difference between their anterior and posterior readings and the 
remaining 11 patients had worse symptoms posteriorly.
S ta t is t ic s
The differences in the scores before and after treatment were analysed using the 
Minitab Statistics package for Windows. Non parametric data were analysed using 
the Mann Whitney U test. Results are shown in Table 2.3
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Table 2.3 Statistics for algesiometer readings before and after treatment
Pre treatment Post treatment
Median value 21 32
95 % Confidence Intervals - 17.98 to -7.0
p value 0.0001
A significant difference was found between the algesiometer readings before and after 
treatment. As this was related to the improvement in the patients’ symptoms, this 
shows that there is good correlation between the algesiometer readings and patients 
symptomatology.
D is c u s s io n
These findings are important when planning surgical management of cases that are 
resistant to medical therapy, as it would appear that in the majority of women with 
W S  there is involvement of all of the glands within the vestibule.
This appears to contradict a recent report arguing for a more conservative surgical 
approach and not including the paraurethral areas in excision margins (Kehoe and 
Luesley 1998).
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We found that the vulval algesiometer gave us the first reported method of quantifying 
tenderness in W S .
It gives us a definitive measurement of tenderness for each clinic visit. These 
readings are recordable and therefore comparable at subsequent visits. It also allows 
different colleagues who may see the patient, a method by which to assess 
improvement or deterioration, and therefore removes the need for the patient to see 
the same clinician at subsequent appointments.
This method was well tolerated and accepted by patients. They found it 
advantageous to see improvement in their readings and with treatment and thus the 
technique provided a form of biofeedback. Often the women seen in our clinic have 
had symptoms for many years and they may not remember what is 'normal'. Many of 
our patients have developed a cycle of avoiding intercourse as they remember it to be 
so painful following development of their vulval symptoms, and so are reluctant to try 
and resume a normal sexual relationship until they have been encouraged to do so by 
the doctor. The algesiometer provides them with the necessary encouragement, as 
they visualise that they can now tolerate a much greater force than was possible prior 
to treatment.
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Conclusion
For the clinician the algesiometer gives a method of quantifying the pain and 
comparing response to treatment and so allows comparison of different types of 
treatment. The vulval algesiometer is used as a non-invasive method of assessing 
and quantifying vestibular tenderness. It is simple to use, gives a recordable result 
and provides the clinician with a reliable method of assessing treatment progress.
The vulval algesiometer has been used in several aspects of the work contained in 
this thesis and will be referred to in later chapters when assessing patient response to 
treatment within our cohort of women with W S .
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CHAPTER THREE - EPIDEMIOLOGICAL CHARACTERISTICS OF 
STUDY PATIENTS WITH VULVAL VESTIBULITIS SYNDROME
W S  continues to be a condition of unknown aetiology. In an attempt to identify causal 
relationships, efforts have been made to identify the population of women that this 
condition affects.
Epidemiological studies have been performed in the USA (Goetsch 1991, Peckham et 
al 1986) and in Sweden (Sjoberg and Nylander 1997), which have compared a cohort 
of patients with W S  to a normal population, to try and define characteristics unique to 
this group of women.
The epidemiological characteristics of British patients with W S  has never been 
investigated and we recognise different cultural factors may apply.
In the population of women attending the Vulval Clinic at the Royal Free it appeared 
that many of the characteristics defined in the literature were exhibited by our patients. 
Therefore we surveyed our population who had been diagnosed with W S  and 
compared our profile with other published data of epidemiological surveys to see if our 
cohort was typical.
Patients with vulval pain represent approximately 13% of attenders at the Royal Free 
Vulval Clinic (MacLean et al 1998) which sees approximately 300 new referrals per 
year (Fig 3.1). Of these just under 10% have W S , with the remainder being 
diagnosed as dysaesthetic vulvodynia. In subsequent years the percentage of women 
presenting with W S  has increased slightly, to around 15%
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Fig 3 .1 Incidence of vulval pathology in 1000 women
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Method
Between August 1996 and August 1998 all new patients who fulfilled Friedrich's 
criteria for W S  were invited to complete a questionnaire. In addition to this all 
patients who had been diagnosed with W S  in the previous 3 years were sent the 
questionnaire by post. In total, 110 questionnaires were sent.
The questionnaire (Appendix 3.1) was divided into 8 sections: general demographic 
information, symptomatology, menstrual history, contraceptive history, sexual history, 
obstetric and gynaecological history, past medical history and a general section 
covering allergies, family history and diet.
90
The telephone number of the investigator was included so if there were any queries 
the patient could contact us.
Patients who were given the questionnaire in the clinic were given the opportunity to 
complete it during their visit, or could choose to complete it at a later date and return it 
by post.
The questionnaires that were sent to previous patients were sent with a covering 
information sheet as to the nature of the study and what would be done with the data 
collected. Previous patients were asked if they were still symptomatic. If so, or if their 
symptoms had recurred, they were given the opportunity of attending the Vulval Clinic 
for review.
Some patients who were successfully treated declined to participate in ongoing 
research, as they thought we would only be interested in patients who still had 
symptoms. A return envelope was included to facilitate replies. Approximately 10% 
of the questionnaires were returned by the Post Office to sender. This is not unusual 
as our cohort is typical of the mobile population within large cities.
Sixty-two questionnaires were returned by the patient, but one had not been fully 
completed and so was discarded. This gave a completion rate of 56%. The 
remaining 61 were entered into a database using Microsoft Access and the results 
analysed.
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Results
D e m o g ra p h ic  d e ta ils
All the patients were Caucasian except one of Asian origin. This ethnic distribution is 
not representative of our general gynaecological referral pattern, or of referrals to the 
Vulval Clinic.
The median age of our cohort was 34.6 years with a range of 22 to 53 years. 
Approximately half of the referrals were from General Practitioners and half were 
tertiary referrals from consultant gynaecologists, dermatologists and genito-urinary 
medicine physicians. Approximately 60% of the referrals were from the London area, 
with the remainder from throughout the UK and 2 patients from abroad.
S y m p to m s
The mean duration of symptoms was 4.5 years (range 9 months - 20 years). Patients 
were asked about different symptoms and requested to assess the severity of their 
symptoms at the onset of the condition and the current severity of symptoms using a 
visual analogue score, on a scale of 0 -10. Some of the patients were new referrals 
and so there was no difference in their analogue scores. Some of the cohort had 
been treated successfully and so overall their scores had decreased.
The mean visual analogue scores of symptoms, at initial presentation and current 
symptoms, of the whole cohort, and those who had been treated or were undergoing 
treatment (excluding the new referrals whose scores were the same), is shown in Fig 
3.2.
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Fig 3.2 Visual analogue scores of symptoms
Visual analogue scores o f symptoms 
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difficulty
It is not surprising that the most troublesome symptom was entry dyspareunia, 
followed by difficulty inserting tampons. Some patients had experienced increasing 
pain or difficulty with coitus or tampon use, to the extent that they were unable to 
continue. Nevertheless they rated the severity of symptoms as the same from onset 
of symptoms to presentation at clinic.
Seventy-six percent of the cohort said that since developing W S  their symptoms had 
been constant rather than intermittent, and symptoms were precipitated with every 
attempt at intercourse. Many experienced post coital burning that could last several 
days after coitus.
i i| I I
■ All initial
■ All current
□ Treated initial
□ Treated current
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Eighty-five percent of the cohort could identify a precipitating factor or event prior to 
which they had been asymptomatic. Five of the patients suggested multiple 
precipitating factors. The most common event that preceded symptoms was an 
episode of illness or infection (28%), most commonly reported as presumed Candida 
infection. Nineteen percent associated commencement of symptoms with a change 
contraception and a further 19% had developed problems post natally. Fourteen 
percent had symptoms precipitated by a new sexual partner and 11% associated it 
with stress, for example at work or in the home, or depression.
Figure 3.3 shows the frequency of perceived precipitating factors.
Fig 3.3 Precipitating factors
Precip ita ting factors
11%
■  Stress
■  1st intercourse
□ Postnatal
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■  Change contraception
■  Post illness/infection
14%
94
H o rm o n a l F a c to rs
Menstrual history
Eighty-six percent of the cohort was premenopausal and 14% post menopausal.
The mean menarche was 13 (range 9.5 -16). Sixty-eight percent were having regular 
menses, of which 39% were controlled by the oral contraceptive pill; the mean cycle 
length was 24.2 days (range 18 - 40). Of the 8 postmenopausal patients, 50% used to 
have regular menses, with the other half having had irregular cycles (range 18 -  45).
A quarter of the patients suffered from dysmenorrhoea. Less than half of the cohort 
(45%) regularly used tampons. Discounting the postmenopausal patients, 3 chose not 
to use tampons and the remainder found their use painful.
These results are summarised in Fig 3.4
The cohort was asked if they noticed any relationship between the severity of 
symptoms and their menstrual cycle. Forty-five percent denied any relationship, 18% 
found that all symptoms were worse during menstruation and 18% noticed a change 
during the early follicular phase of the cycle. Eight percent said problems increased 
mid cycle and 22% during the luteal phase. Several patients reported bimodal 
worsening of symptoms during the menstrual cycle.
Contraception
Patients were asked about current and past contraceptive use.
Thirty percent had abandoned using any contraception. Thirty percent were currently 
using the combined oral contraceptive pill (cOCP) and 70% had used it in the past.
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Over half (52%) had previously used condoms but only 17% were currently using 
them.
A summary of past and present contraceptive use is shown in Fig 3.5.
Fig 3.4 Menstrual history
Relevant menstrual details
Premenopausal Postmenopausal Tampon use Dysmenorrhoea Regular cycle
Fig 3.5 Contraceptive use
Current Contraception
Cap Persona
TAH
Sterilised
Past contraception
None
Condoms
IUCD
cOCP
Diaphragm
PoP Depot Condoms
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When asked whether they thought that their contraception bore any relation to their 
symptoms (19% had associated a change in their contraception with commencement 
of symptoms), 35% reported change in symptoms related to type of contraception 
used. The most frequent response (18%) was symptoms worsening whilst taking the 
combined oral contraceptive pill (cOCP). Two patients had improved on the cOCP 
and one reported improvement in her symptoms during her pregnancy. Eight percent 
were worse whilst using condoms, suggesting that inflammation or allergy to latex may 
have exacerbated the symptoms W S  in this small group of women.
Obstetric history
Forty-seven percent of the cohort had been pregnant in the past. One had conceived 
while symptomatic and her symptoms had improved during the pregnancy.
Thirty-eight percent had children as a result of their pregnancies. Eight percent were 
primiparous and 30% were multiparous. Seventeen percent had had miscarriages 
and 12% had had terminations of pregnancy. One patient had had an ectopic 
pregnancy.
Of the subgroup of 28 patients with children, delivery details are shown in Fig 3.6:
46% had achieved a normal vaginal delivery, 32% had a Caesarean section, 14% had 
Ventouse delivery and 10% had a forceps delivery. Obviously there is overlap 
between the modes of delivery as 78% of this group were multiparous. Sixty-one 
percent (23% of total cohort) had only delivered vaginally and 17% (7% of total cohort) 
had only been delivered by Caesarean section.
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Fig 3 .6 Mode of delivery
Mode of delivery
Ventouse Normal vaginal 
delivery
Forceps
Caesarean section
Three quarters of vaginal deliveries had caused perineal damage. Thirty-two percent 
of this subgroup had an episiotomy and 46% a tear. Just under a third of the 
subgroup had wound healing difficulties, but this represents only 15% of the total 
cohort.
Sixty-four percent of the subgroup breast-fed, with the mean duration of 7.1 months 
(range 1 -36  months). Eighty-seven percent resumed intercourse post natally and the 
mean time to resume intercourse was 6.6 months (range 1 - 60 months). Thirteen 
percent of those who had children, have not had intercourse since, but none of these 
had initially developed symptoms post natally.
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S e x u a l F a c to rs
Coitus
The most striking result of this section is that 50% of the cohort was no longer able to 
have sexual intercourse.
The mean age of first intercourse was 18 (range 12-24)  and the mean number of 
partners was 5.7 (range 1 - 22). Twenty percent of the cohort had only had one 
partner and 13% currently had no partner - the stresses placed on a relationship by 
this syndrome was mentioned frequently. The majority had a single long-term partner 
with the mean length of the current relationship being 7.6 years (range 1 month - 29 
years). Thirteen percent had experienced symptoms with a previous partner but only 
13% reported a new partner precipitated the condition. The majority of the cohort had 
previously had intercourse with their current partner without difficulty. The mean 
frequency of intercourse a week was 2.7 times prior to having W S  and had dropped 
to 0.6 times per week currently, with half of the cohort no longer able to tolerate 
penetrative intercourse. These results are summarised in Table 3.1
Table 3.1 Sexual history
Mean age of 1 st intercourse 18.1 (range 12 - 24)
Mean number o f partners 5.7 (range 1 - 22)
20% only had single partner
Mean time with current partner 92.6 months (range 0 - 350) 
13% currently have no partner
Symptoms with previous partner 13%
Mean frequency of intercourse Pre symptoms: 2.7 / week 
Post symptoms: 0.6 / week
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Infections
When questioned about previous infections, 85% said they had Candida infection in 
the past, but the majority of these had not had confirmatory microbiology. Known HPV 
infection rate was 8% and 7% had previous chlamydia infection. Eighteen percent 
had been diagnosed with bacterial vaginosis. Two patients had vulval herpes simplex 
and 2 had Trichomonas. Two patients had previously had vulval warts. There were 
no cases of gonorrhoea.
P re v io u s  h is to ry
Gynaecological
Thirty-eight percent of the cohort had other gynaecological problems in the past. 10% 
had been diagnosed with polycystic ovaries and 7% with endometriosis. Eight percent 
had a laparoscopy to exclude other pathology without a diagnosis being made. Three 
percent had previous pelvic inflammatory disease and 5% had ovarian cysts. One 
patient had a premature menopause and prolapse and one had a fibroid uterus. 
Eighteen percent had previously had an abnormal smear and the mean duration since 
last smear was 21 months (range 1 -144  months)
Medical
Thirty-eight percent of the cohort had experienced other skin problems with eczema 
elsewhere on the body being the most common (20%). Twelve percent suffered with 
acne and 3% had psoriasis on sites other than the vulva.
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Family
Two patients reported female relatives with vulval problems.
Diet
Thirteen percent reported that diet affected their symptoms with over half of these 
reporting symptoms worsening with alcohol. Only one found a low oxalate diet helpful, 
(Solomons 1991) but some improved with reduced yeast diet.
P re v io u s  tre a tm e n t
The cohort was asked if any treatment they had received had improved their 
symptoms. Considering the high incidence of misdiagnosis and the lack of knowledge 
about this condition, it is not surprising that treatment patterns prior to referral to the 
Vulval Clinic were random. Thirty-eight percent of the cohort had used multiple topical 
creams, but only one patient had experienced relief of symptoms. There was a better 
response in the group who had used steroid based preparations (58%), of which 60% 
had improved. Those who had used Trimovate alone had a 67% response rate.
Six of the 61 patients had undergone vestibulectomy, using the surgical technique 
described by Marinoff (1991) and these had all improved significantly, both clinically 
as well as achieving maximal algesiometer scores, and did not require further 
treatment. The percentage of patients receiving specific treatment and their response 
is shown in Fig 3.7
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Fig 3.7 Response to previous treatment
Effectiveness of treatment
Improvement
Previous treatment
Discussion
Epidemiological data about British women with W S  is uncommon. The results of this 
epidemiological survey have been compared with published data from around the 
world. Our prevalence of 10-15% is comparable with that reported by Goetsch (1991), 
although her prevalence was from a private general gynaecological clinic and not a 
specialist vulval clinic. The predominance of Caucasian women is also previously 
reported.
Our median age of 34.6 years is comparable with Goetsch's population but 
significantly higher than the Swedish population who were all under 26 years (Sjoberg 
et al 1997).
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In view of the fact that some of our patients had symptoms for over a decade, it is not 
surprising that our age range is higher.
VVS is still a relatively unknown condition and this is reflected in the duration of 
symptoms and the length of time before women are referred to a Vulval Clinic. Often 
patients have been examined by multiple clinicians and no diagnosis made. Even 
once a diagnosis is reached treatment is not straightforward and there is no instant 
solution.
P s y c h o lo g ic a l e ffe c ts  o f  W S
Often in the absence of obvious physical abnormality, the suggestion that the 
condition is psychosomatic or purely psychological is raised. This frequently leads to 
antagonism between the patient and the clinician, and can destroy the trust the 
woman needs to feel within the doctor patient relationship in order to manage this 
condition successfully. It is easy to imply that “all is in the mind” when no 
straightforward physical solution is available. Unfortunately this attitude may be 
reflected by the woman’s partner and may even be seen by the partner as an excuse 
to avoid physical contact. The stresses that this places on a couple are great and this 
condition has been cited as contributing to the breakdown of relationships.
Studies into the psychological effects of vulval disease have been published. Often 
the making of a diagnosis is enough to ease some of the tension. Many of our cohort 
reported that they were relieved to finally have a diagnosis and to be able to put a 
name to the symptoms that they had been unable to explain. Stewart et al (1994)
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showed that women with vulvodynia have a greater degree of psychological stress 
than women with other vulval pathology, but women who have vulvodynia with an 
identifiable cause have less stress than those with essential or dysaesthetic 
vulvodynia.
Jantos and White (1997) highlighted the parallelism between women with VVS and 
somatisation disorders, but we did not find any significant evidence of this in our 
cohort.
Q u a n tif ic a tio n  o f  s y m p to m s
In the literature, most authors have not asked their cohort to quantify pain. We used 
a visual analogue score to quantify symptoms, where a score of 0 indicates the patient 
is asymptomatic, and a score of 10 indicates the patient cannot imagine the symptom 
becoming worse. By asking the cohort to do this for all five categories of vulval 
burning, dyspareunia, pruritus, discharge and difficulty in tampon use we were able to 
establish the significance they attached to each symptom. Jantos and White (1997) 
previously used a similar method to look at dyspareunia within vulval pain syndromes 
and found their cohort had a mean pain rating of 8.5. Our initial mean rating for 
dyspareunia was 7.6 and was our highest ranked symptom. Less importance was 
attributed to pruritus and discharge. This is not surprising, as although pruritus is a 
prominent feature of other vulval pathologies it is not a classical symptom of VVS.
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Aetioloaical Factors
Hormonal
Use of the combined oral contraceptive pill (cOCP) has been implicated in the 
aetiology of VVS. Sjoberg and Nylander (1997) found their patients with VVS had 
used the cOCP for a significantly longer time than a control group, and Bazin et al 
(1994) found a greatly increased relative risk with early use of the cOCP. Other 
studies have not looked at this in depth.
In our study the combined oral contraceptive pill was the most widely used method of 
contraception, but equivalent numbers were no longer using any contraception, due to 
their sexual inactivity. About three-quarters of the cohort had used the oral 
contraceptive pill in the past.
Previous studies have not commented on change in symptoms with different 
contraceptive use. We found the most common change was that symptoms had 
worsened with the oral contraceptive pill (18%) and of those who thought their 
symptoms had started with a change of contraception most commonly it was when 
they had started the pill.
We know that the combined oral contraceptive pill suppresses measured endogenous 
oestrogen (Gilmer et al 1980). We also know that breast-feeding women are hypo 
oestrogenised. The group of women whose symptoms improve when they stop the 
contraceptive pill or breast feeding gives rise to the theory of a possible hormonal 
aetiology of Vulval Vestibulitis Syndrome. This has not been researched in the 
literature but is investigated and discussed further in chapter 5.
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VVS is assumed to be a condition that affects younger women, however 14% of our 
cohort were post menopausal, having had symptoms for up to 20 years, although all 
had been premenopausal when the condition started. It has been reported that early 
menarche may be associated with an increased relative risk of developing VVS (Bazin 
et al 1994), but with our median age of menarche being 13 our cohort does not fall into 
this category. This characteristic is in concordance with previous studies (Peckham et 
al 1986), as was cycle length and the 25% of patients suffering dysmenorrhoea. Half 
of our patients thought that their symptoms were cyclical but there was no correlation 
with a particular time of cycle. Schover et al (1992) commented specifically on pain in 
relation to the menstrual cycle, having found their cohort experienced exacerbation of 
symptoms in the late luteal phase. We found that only 16% of our population thought 
that pain was worse at one point during their menstrual cycle but there was no 
correlation with phases of the cycle.
Wide variation was found with reported tampon use. Peckham et al (1986) quoted 
that all of his patients used tampons, whereas Goetsch (1991) found that three 
quarters of her cohort did not use tampons. In our study just under half regularly used 
tampons (45%), although a few in this group found them uncomfortable, but not 
painful.
The incidence of post partum vestibulitis (Goetsch 1991, Woodruff and Parmley 1983) 
is reported as greater than found in our study. Vaginal delivery was not a precipitating 
factor frequently found in our population. (Fig 3.6) As previously mentioned, mode of
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delivery, and therefore perineal trauma do not appear to be relevant, but other studies 
have not investigated this. Breast-feeding appeared to be more important, as a 
proportion of the women who developed symptoms post delivery improved when they 
stopped breast-feeding.
Sexual
The majority of our cohort could identify a precipitating factor. Goetsch (1991) 
postulated the existence of primary and secondary vestibulitis. Primary vestibulitis is 
dyspareunia experienced from first coitus. Secondary vestibulitis is when symptoms 
develop later, having previously had painfree penetrative intercourse. If these 
definitions are applied to our population, the proportion of the cohort who had 
symptoms from first intercourse is low at 8%. This conflicts evidence from Canada 
when a study found 43.9% of their surveyed cohort experienced dyspareunia 
compatible with Vulval Vestibulitis Syndrome, at first coitus (Bazin et al 1994).
The same study demonstrated an increased relative risk with early sexual activity 
before 16 years of age. The median onset of first intercourse in our group was 18, 
and only 6 patients in our group were less than 16 years old at first coitus, and so data 
from our cohort does not support this theory. As previously reported, frequency of 
sexual intercourse falls dramatically with onset of this condition, and with half of our 
cohort abstaining totally, this shows what an impact this condition has on women’s 
lives.
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Peckham et al (1986) reported that 60% of his cohort had new partners within 6 
months of developing symptoms, but in our cohort only 13 % associated symptoms 
starting with a new partner. However the majority of our patients had not had 
symptoms with a previous partner, but as the median length of current relationship 
was 7.6 years and median duration of symptoms 4.5 years this is not surprising.
The most common precipitating event in our cohort was a health event or infection.
A large proportion attributed commencement of symptoms to an episode of fungal 
infection, but these were not microbiologically proven episodes. It is widely assumed, 
both by the public and the medical profession that any vulval symptoms are caused by 
Candida infection, and so it is not possible to distinguish between genuine, possibly 
causative infections and misdiagnosis. This problem also affects the initial treatment 
given prior to referral.
Previous treatment
When questioned about previous treatment again the variation in approach was 
highlighted, as was the difficulty in achieving successful treatment results. The 
minimal improvement in the group who had multiple topical creams shows that unless 
there is superimposed fungal infection, anti fungal treatment has no place in treatment 
of W S . This contradicts evidence suggesting it should be first line treatment 
(Morrison et al 1996).
As mentioned previously, many vulval patients report improvement having only 
achieved a diagnosis. If this is true, then the initial physical therapy is irrelevant, as a
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proportion would have improved without physical treatment. Equally, the placebo 
effect in vulval disease is poorly understood. Some patients find relief with any topical 
cream, and it may be the emollient vehicle that is effective and not the active 
ingredients.
The total success of the patients in our cohort who had surgery is higher than the 
recognised figure (Marinoff and Turner 1991) but the numbers in our group were small 
and may represent patient selection. Surgery is not the first line treatment of Vulval 
Vestibulitis Syndrome in this country, as it is elsewhere in the world, particularly in 
parts of the United States, but it appears to be successful. Why removing this skin 
that has no histopathological abnormality works, however remains unknown. In our 
unit we only operate on patients who have “failed” all medical treatment and in whom 
all other causes of the vulval symptoms have been excluded and so represent women 
with more severe or resistant disease
Other factors
Diet affecting symptoms has been postulated and low oxalate diets recommended as 
treatment in the past (Solomons et al 1991), but only 13% of our cohort found any 
relationship between diet and symptoms. In those who did, alcohol was the most 
common factor exacerbating symptoms. Only one patient improved on the low 
oxalate diet.
Genetic factors have also been suggested and high rates of affected female relatives 
have been expressed (Goetsch 1991), but we found only 2 patients who had female 
relatives with similar difficulties.
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Conclusion
The assumption that W S , although a physical problem, has some psychological 
component is reasonable, but it is difficult to distinguish whether this causes 
symptomatology or is a result of it. Many patients have come to clinic having been 
given multiple diagnoses and treatments by different clinicians and there is an obvious 
underlying fear of not being believed. Equally many of these women have had 
symptoms for such a long period of time that they can no longer remember what is 
“normal” and are beginning to question their own judgement.
Our data from British patients appear comparable with other studies elsewhere in the 
world. There does not appear to be a specific pattern developing to characterise 
women with this condition, apart from the symptoms that they all suffer. Obviously as 
the aetiology remains unclear, this presents continuing difficulty for the clinician in 
establishing the best method of treatment for their patient.
Many aetiological factors have been investigated and excluded. Our epidemiological 
data show that many factors that appear to affect this condition are hormonal. With 
the exception of the few studies mentioned, these factors have been largely ignored 
and there has not been formal investigation into hormonal aetiology.
This issue is addressed in chapter 5.
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CHAPTER FOUR ■ IS VULVAL VESTIBULITIS SYNDROME AN 
INFLAMMATORY CONDITION?
Introduction
There is a growing belief that if VVS is not an infection, it is the result of an 
inflammatory process. Histopathological studies have failed to recognise specific 
features unique to this condition, but chronic inflammatory infiltrates are consistently 
seen (Pyka et al 1988). The histopathological appearance of a normal vestibule, 
stained with Haematoxylin and Eosin is shown in Fig 1.2.
Inflammation is the response of a vascularised tissue to local injury. Inflammation 
causes vascular damage, leading to hyperaemia, and this would account for the 
vestibular erythema seen in W S .
Pro-inflammatory mediators, including cytokines, regulate inflammation.
Cytokines are soluble proteins, which act as chemical communicators between cells 
but not as effector molecules within their own right.
Tumour Necrosis Factor (TNF)-a is a cytokine secreted by activated monocytes and 
macrophages and is a potent endocrine and paracrine mediator of inflammation. It 
interacts with other inflammatory mediators such as histamine and substance P to
i l l
promote neurogenic inflammation. It has a particular effect on Interleu kin-1(3 (IL-1 (3) 
by providing a positive feedback loop to promote increased production of IL1-(3 and 
release of other cytokines.
IL-1 cytokines are polypeptides that are centrally involved in the genesis and 
maintenance of the inflammatory response, their major physiological source being the 
activated macrophage. They cause prostaglandin release via action on fibroblasts 
and can act on endothelial cells to promote TNFa release. IL-1a and 1p, along with 
TNFa are important inducers of the acute phase response of inflammation (Sims and 
Dower 1994). TNF receptors are present on nearly all cell types except erythrocytes 
and resting T cells and IL-1 receptors are found on all nucleated cells (Thompson 
1994).
If W S  is an inflammatory condition, my hypothesis is that tissue from patients with 
W S  should have greater expression of inflammatory markers than tissue from normal 
controls.
Only one previous study has investigated TNFa in W S  patients, but used ELISA 
techniques on homogenised tissue (Foster and Hasday 1997). My contribution is to 
demonstrate TNFa, IL-1 a and 1p using immunohistochemistry, which allows the 
spatial relationship of proteins to be assessed maintaining tissue morphology. 
Expression of these cytokines in women with W S  could then be compared to 
expression in normal vestibular tissue.
Immunohistochemistrv: the Theory
Immunohistochemistry is the process of staining tissue with antibodies to identify a 
particular protein expression, and to demonstrate the positioning of such proteins 
within a tissue. The protein that is being investigated has antigenic properties and 
expresses epitopes, to which the antibody binds. A visible marker is attached to the 
antibody, thereby making the protein visible under microscopic analysis.
Antibodies are proteins produced in response to 'foreign1 material that acts as an 
antigen, by B-lymphocytes in the spleen. Monoclonal antibodies are derived from a 
single B-cell and are therefore specific in their origin. This property is used in 
immunohistochemistry to obtain specificity within a reaction and thus allow 
identification of expression of a particular protein.
Polyclonal antibodies are derived from several B cell lines and so are not specific.
Both monoclonal and polyclonal antibodies may be used in immunohistochemistry but, 
as the process is usually trying to identify a particular protein, monoclonal antibodies 
are used more frequently, if they are available, as they are more specific.
P ro d u c t io n  o f  m o n o c lo n a l a n tib o d ie s
1) Immunisation
A particular protein, which acts as an immunogen, is injected into a small animal such 
as a mouse. The mouse then mounts an immune response and produces antibodies 
to the injected protein. The B-cells are then removed from the mouse spleen or lymph
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node. To obtain the monoclonal antibody it is necessary to isolate the specific B-cell 
from the other B-cells. This is performed in tissue culture where proteases dissociate 
cell clusters in the medium into single cells, which can then be isolated.
2) Fusion and selection
The B-cell is capable of cloning itself, but will have a finite lifespan. In order to prolong 
cell life and promote cell division the B-cell is fused with a myeloma cell to form a 
hybridoma. This then replicates at a greater rate and so will produce a large number 
of antibodies.
3) Screening
To obtain the desired antibody, screening enables selection of the specific antibody 
and non-specific antibody growth is discarded.
4) Characterisation
This involves further analysis of the antibody for specificity and also analyses reactivity 
and cross-reactivity. Included in this process is assay restriction, which involves 
profiling the antibody in different assay systems. This is important for the antibody's 
potential as a diagnostic reagent, as some monoclonal antibodies will perform well in 
some systems but not in others.
Once the specific antibody is made, bulk production can then be achieved using 
surface expanded tissue culture flasks or hollow fibre systems (Nelson et al 2000).
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There are a variety of techniques and methods employed in immunohistochemistry. 
The following gives a brief account of the methods used in this project.
Indirect 2 Step Method
In this method the primary antibody reacts with the antigen in the tissue. The 
secondary antibody is labelled with the visible enzyme, and the secondary antibody 
binds to the primary antibody. The secondary antibody must be directed against the 
species that the primary antibody is derived from. This process enables several 
different antibodies to bind with different epitopes on the primary antibody, which 
means that more markers will be attached at the site of the antigen. Therefore, this 
procedure will give better results with increased intensity of staining, and will be more 
specific.
The problem with this is that there is a greater chance of cross-reactivity with this 
method, which will result in increased non-specific background staining. This is 
overcome by using secondary serum from the same species as the tissue under 
investigation (i.e. human) which will 'mop up’ non-specific endogeneous 
immunoglobulin.
This method was used throughout this project.
Avidin-Biotin Method
This method uses the high affinity of avidin or streptavidin for biotin therefore making it 
a more sensitive method. Biotinylation is the process by which biotin is covalently
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attached to the antibody. The secondary antibody is biotinylated and horseradish 
peroxidase is used as an enzyme label. This method has been found to be more 
sensitive than other immunohistochemical methods and has excellent results on fixed, 
paraffin embedded tissue.
U se o f  e n zym e s  in  im m u n o h is to c h e m is try
Immunohistochemical methods use enzyme-substrate reactions to produce coloured 
end-products which are visible under the microscope from colourless chromogens.
Enzymes used in immunohistochemistry should have the following properties:
1) The bound enzyme should be stable in solution.
2) The enzyme should be available in a highly purified form.
3) Conjugation or non-covalent binding should not abolish enzyme activity.
4) Enzyme activity should interfere minimally with specific antigen related staining.
5) Products of reactions should be readily detectable and stable.
Enzyme labels  -  Horseradish Peroxidase and DAB
These reagents are suitable for labelling as the haeme group within the horseradish 
peroxidase reacts with hydrogen peroxide to form a complex, which then decomposes 
to water and atomic oxygen. This reaction can then oxidize an electron donor, such 
as 3,3'-diaminobenzidine (DAB), which then converts from a colourless compound to 
a coloured (brown) product and therefore can be used as a chromogen.
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E s ta b lis h in g  c o r re c t  d ilu t io n s
In order to obtain optimal results, immunohistochemistry should produce staining of 
sufficient intensity to be clearly visible for the protein under investigation, with minimal 
background staining of the surrounding tissue.
Antibody titre is defined as the highest dilution of an antiserum that results in optimal 
specific staining with least amount of background staining.
The highest dilution of a substance is governed by the affinity of the antibody. A high 
affinity antibody is likely to react faster with an antigen, to produce a more intense 
stain in a shorter incubation period. Low affinity antibodies may need a longer 
incubation period to achieve the same intensity of stain. Long incubation periods 
should be performed in a humidity chamber to prevent evaporation and drying out of 
tissue sections. Equally, higher dilutions can be used with longer incubation times. 
Incubation temperatures may also vary, but commonly are at room temperature or 
4°C. Experimental data with small quantities of different dilutions are often necessary 
to establish optimum dilution prior to proceeding with the main staining experiment.
A n tig e n  R e tr ie v a l
When using tissue in paraffin-embedded sections, the antigens sometimes need to be 
retrieved from the tissue in order for them to be available to bind freely with the 
antibody that is being used for the investigation. This may be performed using 
microwaving or protease digestion. Therefore, when designing an
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immunohistochemical protocol on paraffin-embedded sections, often all antigen 
retrieval methods are tried during trial experiments, and compared to no antigen 
retrieval, to see which method gives the best results, before the study experiments are 
performed.
In this study, microwaving was performed in 10mM sodium citrate buffer (pH 6.0) in a 
microwave at full power for 5 minute bursts twice. Protease digestion used 125}xg/ml 
PBS, Bacterial Type XXIV protease (P-8038, Sigma) for 7.5 minutes at 37°C.
C o n tro ls
Controls are vital for validation of immunohistochemistry and should be included in 
any staining procedure.
Positive controls
Positive controls were used throughout this project, appropriate for each target tissue. 
Tissue known to contain the target antibody, was used for each experiment.
For oestrogen receptor expression, breast cancer tissue with known oestrogen 
receptor positive status was used. For cytokine expression, breast or ovarian cancer 
tissue was used
Negative controls
Negative controls were used in each experiment. These were the same tissue 
specimens used for the positive control, but addition of the primary antibody was 
omitted and replaced by the buffer being used.
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B a c k g ro u n d  S ta in in g
Background staining is the result of endogeneous enzyme activity. This results from 
decomposition of hydrogen peroxide by haeme proteins such as haemoglobin 
contained within tissue samples. This can be overcome by addition of hydrogen 
peroxide during the staining process to absorb any excess activity.
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STUDY
Methods and Materials
Following ethical approval, 35 tissue samples from the vestibule of the vulva were 
obtained from patients who fulfilled Friedrich's criteria of W S . This was performed 
either at vestibulectomy in patients undergoing surgical treatment, or from outpatient 
biopsy using a 4mm Stiefel punch.
Some of the women had previously had medical treatment including topical steroids 
and topical oestrogen, but none of the women were using medical treatment at the 
time the biopsies were taken. Six of the group were currently using the OCP and one 
was postmenopausal.
Following approval from the local Ethics Committee, sixteen samples of normal 
vestibular tissue were obtained from women undergoing unrelated gynaecological 
surgery. All of these women were asymptomatic and not taking hormonal 
contraception.
All of the control group and all but one of the study group were premenopausal. In 
both groups all the women were Caucasian and the controls were selected to age 
match the study group.
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All tissue samples were fixed in 10% neutral buffered formalin and embedded in 
paraffin wax. Five micrometre sections were cut and placed on 3- 
aminopropyltriethoxysilane-coated glass slides.
The slides were stained with haemoxylin and eosin and were reviewed by a 
pathologist to exclude other pathology.
S p e c if ic  Im m u n o h is to c h e m ic a l s ta in in g  te c h n iq u e s
TNFa
Immunohistochemical staining for TNFa was performed using a standard streptavidin 
biotin technique with a commercially available monoclonal antibody to TNFa.
Trial experiments were performed using different dilutions of antibody to establish the 
correct dilution of primary antibody to obtain optimal staining. Dilutions varied 
between neat application of the antibody and 1:50. Optimal staining with positive 
results but no background staining was reached using a dilution of 1:5.
Experiments for antigen retrieval were performed using microwaving and protease 
digestion, and varying incubation of either 1 hour or overnight was tried. Different 
temperatures of either 4°C or room temperature were also tried for the incubation 
period. The final full protocol is shown in Appendix 4.1.
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Positive control tissue was breast cancer, and a negative control where the primary 
antibody was omitted, was used for each immunohistochemical experiment. Staining 
was repeated four times to ensure staining reproducibility.
Positive expression of TNF-a stained brown; slides were counterstained with 
haematoxylin. Negative expression stained blue.
IL-1 a
Immunohistochemical staining for IL1a was performed using a standard streptavidin 
biotin technique, using a commercially available antibody to IL1a.
Trial experiments were performed using different dilutions of antibody to establish the 
correct dilution of primary antibody to obtain optimum staining. Dilutions varied 
between 1:5 and 1:100. Optimal staining with positive results but no background 
staining was reached using a dilution of 1:20.
Experiments for antigen retrieval were performed using microwaving and protease 
digestion, and varying incubation of either 1 hour or overnight was tried. Different 
temperatures of either 4°C or room temperature were also tried for the incubation 
period. The final full protocol is shown in Appendix 4.2.
Positive control tissue was ovarian cancer, and a negative control where the primary 
antibody was omitted, was used for each immunohistochemical experiment. Staining 
was repeated four times to ensure staining reproducibility.
Positive expression of IL-1 a stained brown; slides were counterstained with 
haematoxylin. Negative expression stained blue.
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IL1B
Immunohistochemical staining for IL1p was performed using a standard streptavidin 
biotin technique, using a commercially available antibody to IL1p.
Trial experiments were performed using different dilutions of antibody to establish the 
correct dilution of primary antibody to obtain optimal staining. Dilutions varied 
between 1:50 and 1:500. Optimal staining with positive results but no background 
staining was reached using a dilution of 1:100.
Experiments for antigen retrieval were performed using microwaving and protease 
digestion, and varying incubation of either 1 hour or overnight was tried. Different 
temperatures of either 4°C or room temperature were also tried for the incubation 
period. The final full protocol is shown in Appendix 4.3.
Control tissue was ovarian cancer, and a negative control where the primary antibody 
was omitted, was used for each immunohistochemical experiment. Staining was 
repeated four times to ensure staining reproducibility.
Positive expression of IL-1 p stained brown; slides were counterstained with 
haematoxylin. Negative expression stained blue.
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Analysis of staining
The sections were analysed by light microscopy (x200 magnification: x10 eyepiece, 
x20 objective) by two independent observers who were unaware whether the section 
was from a control or a VVS patient. Less than 5% discrepancy was found in most of 
the scores, but in sections where the result was inconsistent, the slide was re­
examined by both observers and agreement reached.
As the samples were small the whole section, i.e. the dermis and epidermis, was 
analysed.
S c o r in g  S y s te m s
TNFa
All the samples that showed expression of TNF-a, stained positive in more than 50% 
of the whole sample (i.e. dermis and epidermis), therefore the samples were said to 
be positive for TNFa expression if they showed any positive staining (i.e. >50%). A 
negative result, i.e. not expressing TNFa, was only recorded if the whole sample was 
negative.
IL-1a
The dermis and epidermis of the whole section were analysed. Nuclear and 
cytoplasmic staining was recorded separately. Degree of expression was recorded as 
positive if the whole section expressed IL-1a, mainly positive if the positive areas were
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much greater than the negative areas (i.e. >60%), negative if the whole section did not 
express IL1a and mainly negative if the negative areas were far greater than the 
positive areas (i.e. >60%). Intensity of staining was not formally assessed, as all 
sections were similar.
IL1B
Nuclear and cytoplasmic staining of the whole sample, i.e. dermis and epidermis were 
recorded. Degree of expression was recorded as positive if the whole section 
expressed IL-1p, mainly positive if the positive areas were much greater than the 
negative areas (i.e. > 60%), negative if the whole section did not express IL-1p and 
mainly negative if the negative areas were far greater than the positive areas (i.e. 
>60%).
Intensity of staining was not formally assessed, as all sections were similar, although 
the intensity was reduced overall in comparison to the staining seen in the sections 
expressing IL-1a, probably because it was a polyclonal antibody.
S ta t is t ic s
Statistical analysis was performed using the Minitab Statistics package for Windows.
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Results
When the sections were analysed under the microscope, it became obvious that the 
differences between the sample from the controls and the VVS patients could be seen 
only in the epidermis. Therefore the results below are for cytokine expression in the 
epidermis of the vestibular tissues.
T N F a
Table 4.1 shows the comparison of TNF-a expression between the two groups.
Table 4.2 shows the results of TNFa expression in the sections.
Only 11 % (n=4) of the vestibulitis cohort stained positive for expression of TNF-a, with 
89% (n=31) showing no expression of TNF-a in any layer of the specimen. However 
56% (n=9) of the control samples expressed TNF-a with the minority of the cohort 
(44%, n=7) showing no expression of TNF-a. The samples from the patients with W S  
showed less expression of TNFa than the control tissue, with the majority of the VVS 
not expressing TNFa at all.
Using a Chi-Squared test, these results show a statistically significant difference
(p=0.001).
Table 4.1 Results: Summary of TNF-a expression
STAINING W S CONTROL
POSITIVE 11 % (n=4) 56% (n=9)
NEGATIVE 89% (n=31) 44% (n=7)
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Table 4.2 TNF a  results: VVS and controls
SUBJECT SAMPLE RESULT CONTROL SAMPLE RESULT
975954 P Negative 1 P Positive
976017 V Negative 2 P Positive
921212 V Negative 3 P Negative
94419 V Positive 4 P Negative
978704 p Negative 5 P Positive
971668 V Negative 6 P Negative
963371 V Negative 7 P Positive
974024 V Negative 8 P Negative
946844 V Negative 9 P Positive
94861 V Negative 12 P Positive
943709 V Positive 13 P Positive
956595 V Negative 14 P Negative
972740 V Negative 17 P Positive
190697 p Negative 18 P Positive
190697b p Negative 20 P Negative
190697c p Negative 21 P Negative
979632 p Negative
9711579 p Negative
943708 V Negative
954773 V Negative
916353 V Negative
9712093 V Negative
975629 p Negative
9713276 p Negative
953949 V Negative
973858 p Negative
9712432 p Positive
94169 V Negative
978868 V Negative
97474 V Positive
9610453 p Negative
968886 p Negative
95436 V Negative
9714579 p Negative
975839 V Negative
P = Punch biopsy 
V = Vestibulectomy specimen
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Sections from control and W S  tissue, expressing TNFa are shown in Figs 4.1 and 4.2 
Fig 4.1 TNF- expression in VVS tissue
Fig 4.2 TNF- expression in control tissue
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IL-1a
A marked difference was again obtained between expression of IL-1a in tissue from 
women with VVS and the control tissue. All but one (n=15) of the control specimens 
demonstrated positive nuclear expression of IL-1a, and in the remaining sample there 
was some minor degree of expression. In comparison 65% (n=22) of the W S  
samples were negative, or mainly negative, with one third (n=12) of the specimens not 
expressing IL-1a in any layer of the section. Cytoplasmic staining did not show such a 
marked difference, although 16% (n=6) of the W S  samples were entirely negative, 
whereas all of the control samples exhibited some expression.
Tables 4.3 and 4.4 show the results from both groups.
Using a Chi Squared test to analyse the difference between positive and negative 
staining between the W S  group and the control group, a statistically significant 
difference was found in nuclear staining (p=0.0005), but not in the cytoplasmic 
staining (p=0.2)
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Table 4.3 IL-loc VVS Results
SUBJECT SAMPLE RESULT
(nuclear)
RESULT
(Cytoplasm)
975954 P Positive Positive
976017 V Pos + Neg Positive
921212 V Negative Positive
94419 V Negative Positive
978704 p Neg ,Occ Pos Positive
971668 V Negative Negative
963371 V Neg + Pos Positive
974024 V Negative Positive
946844 V Negative Negative
94861 V Negative Positive
943709 V Pos Occ Neg Positive ++
956595 V Pos + Neg Positive
972740 V Neg + Pos Positive
190697 p Negative Negative
190697b p Negative Positive
190697c p Positive Negative
979632 p Negative Positive
9711579 p Negative Positive
943708 V Neg,Occ pos Positive
954773 V Pos + Neg Positive
916353 V Neg, Occ Pos Positive
9712093 V Positive Positive
975629 p Neg + Pos Positive
9713276 p Positive Positive
953949 V Negative Neg + Pos
973858 p Pos + Neg Positive
9712432 p Pos + Neg Positive
94169 V Positive Positive
978868 V Neg + Pos Pos + Neg
97474 V Neg + Pos Positive
9610453 p Pos + Neg Positive
968886 p Positive Negative
95436 V Negative Negative
9714579 p Neg + Pos Positive
975839 v -l Neg + Pos Positive
P= Punch Biopsy Neg+Pos = mainly negative
V= Vestibulectomy Pos+Neg = mainly positive
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Table 4.4 IL -la  Control Results
CONTROL SAMPLE RESULT
(nuclear)
RESULT
(cytoplasm)
1 P Pos, Occ Neg Neg + Pos
2 P Pos + Neg Positive
3 P Pos, Occ Neg Positive
4 P Pos + Neg Pos + Neg
5 P Pos + Neg Positive
6 P Pos + Neg Positive
7 P Pos + Neg Positive
8 P Neg + Pos Positive
9 P Pos, Occ Neg Positive
12 P Pos + Neg Positive
13 P Pos, Occ Neg Positive
14 P Pos, Occ Neg Positive
17 P Pos + Neg Positive
18 P Pos + Neg Positive
20 P Pos + Neg Positive
21 P Pos + Neg Positive
P = Punch biopsy Neg+Pos = mainly negative
V = Vestibulectomy specimen Pos+Neg = mainly positive
Table 4.5 shows the comparison of IL-1a expression between the two groups 
Sections from control and W S  tissue, expressing IL-1a are shown in Figs 4.3 and 4.4.
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Fig 4.3 IL-1 expression in VVS tissue
;V'VW<: * - ■/;;;
Fig 4.4 IL-1 expression in control tissue
Table 4.5 Results: Summary of IL-1 a expression
STAINING W S CONTROL
NUCLEAR
Negative 35.5% (n=12) 0% (n=0)
Mainly negative 29% (n=10) 6.25% (n=1)
Positive 16.1% (n=6) 0% (n=0)
Mainly positive 19.4% (n=7) 93.75% (n=15)
CYTOPLASMIC
Negative 16.1% (n=6) 0% (n=0)
Mainly negative 3.2% (n=1) 6.25% (n=1)
Positive 77.5% (n=27) 87.5% (n=14)
Mainly positive 3.2% (n=1) 6.25% (n=1)
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IL-10
There was little nuclear expression of IL-1 p in both the W S  and control samples. 
Results are shown in Tables 4.6 and 4.7
All but one (97%, n=34) of the W S  specimens did not show any nuclear expression of 
IL-1 p in any layer of the section, and 94% (n=15) of the control tissue was negative, or 
mainly negative. However positive staining was seen in the cytoplasm of all the 
controls and 87% of the W S  samples. Using a Chi Squared test, there was no 
statistically significant difference between the nuclear staining (p=0.3), or the 
cytoplasmic staining (p=0.29).
Table 4.6 IL-1 p Control Results
CONTROL SAMPLE RESULT
(nuclear)
RESULT
(cytoplasm)
1 P Neg + Pos Posit ve
2 P Negative Posit ve
3 P Negative Posit ve
4 P Negative Posit ve
5 P Neg + Pos Posit ve
6 P Neg + Pos Posit ve
7 P Negative Posit ve
8 P Negative Posit ve
9 P Negative Posit ve
12 P Neg + Pos Posit ve
13 P Negative Posit ve
14 P Neg + Pos Posit ve
17 P Neg + Pos Posit ve
18 P Neg + Pos Posit ve
20 P Pos + Neg Posit ve
21 P Negative Posit ve
P= punch biopsy Neg+Pos = mainly negative
Pos+Neg = mainly positive
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Table 4.7 IL-1 p VVS Results
SUBJECT SAMPLE RESULT
(nuclear)
RESULT
(cytoplasm)
975954 P Negative Neg + Pos
976017 V Negative Negative
921212 V Neg, Occ Pos Positive
94419 V Negat ve Positive
978704 p Negat ve Positive
971668 V Negat ve Positive
963371 V Negat ve Positive
974024 V Negat ve Neg + Pos
946844 V Negat ve Neg + Pos
94861 V Negat ve Positive
943709 V Negat ve Pos + Neg
956595 V Negat ve Positive
972740 V Negat ve Positive
961552 V Negat ve Positive
190697 p Negat ve Pos + Neg
190697b p Negat ve Positive
190697c p Negat ve Pos + Neg
979632 p Negat ve Positive
9711579 p Negat ve Positive
943708 V Negat ve Positive
954773 V Negat ve Positive
916353 V Negat ve Positive
9712093 V Negat ve Positive
975629 p Negat ve Positive
9713276 p Negat ve Positive
953949 V Negat ve Positive
973858 p Negat ve Positive
9712432 p Negat ve Positive
94169 V Negat ve Positive
978868 V Negat ve Positive
97474 V Negat ve Positive
9610453 p Negat ve Positive
968886 p Negat ve Positive
95436 V Negat ve Positive
9714579 p Negat ve Positive
975839 V Negat ve Positive
P = Punch biopsy Neg+Pos = mainly negative
V = Vestibulectomy specimen Pos+Neg = mainly positive
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Table 4.8 Results: Summary of IL-1 p expression
STAINING W S CONTROL
NUCLEAR
Negative 97% (n=34) 50% (n=8 )
Mainly negative 3% (n=1) 44% (n=7)
Positive 0 % (n=0 ) 0 % (n=0 )
Mainly positive 0 % (n=0 ) 6 % (n=1)
CYTOPLASMIC
Negative 3% (n=1) 0 % (n=0 )
Mainly negative 10% (n=3) 0 % (n=0 )
Positive 77%  (n=28) 0 % (n=0 )
Mainly positive 10% (n=3) 100% (n=16)
Table 4.8 shows the comparison of IL-1 p expression between the two groups. 
Sections from control and W S  tissue, expressing IL-1 p are shown in Figs 4.5 and 4.6.
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Fig 4.5 IL-1 expression in VVS tissue
Fig 4.6 IL-1 expression in control tissue
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Discussion
From these results it would appear that VVS may not be an inflammatory condition.
IL-1 and TNFa expression in vulval tissue in women with W S  has only been 
previously described in one study. Foster and Hasday (1997) performed ELISA on 
vulval tissue homogenates from 12 women with W S  and 10 normal controls, 
undergoing posterior repair, and found a 1.8 fold increased expression of TNF-a and 
2.3 fold increased expression of IL-1 p in women with W S  compared to an 
asymptomatic control group. Statistical analysis showed that the results were 
approaching significance (p=0.07). However, IL-1 a was not examined and my study 
is the first study to do so.
Of interest, Foster’s study found a significant paradox: when different areas of the 
vulva were analysed, the anatomical areas with the highest hyperalgesia expressed 
2.2 fold less TNFa than areas elsewhere on the vulva that were not as symptomatic. 
Also when analysed by anatomical site, the difference between the W S  patients and 
controls was not significant. This led to the suggestion that cytokines were not likely 
to be the final common pathway, but that they acted on the vestibule secondarily 
through the release of neurokines.
In order to try and explain this phenomenon it is necessary to examine other 
mediators of inflammatory processes.
A previous study has examined Natural Killer (NK) cell activity in women with W S  
compared to a control group. NK cells secrete cytokines, including TNFa, and the
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group found that W S  patients had significantly less NK activity (with some samples 
showing no activity at all), compared to the controls (Masterson et al 1996). The study 
suggested that NK activity could be increased in response to stimulation with IL2 or 
interferon but NK activity still remained significantly impaired compared with the 
controls.
This lack of NK activity could lead to decreased TNFa and IL-1 expression, as seen in 
our results.
Lack of TNFa expression has been reported in other gynaecological pathology. For 
example, a study looking at TNFa expression in normal and abnormal cervix uteri 
found that the cytokine was expressed in normal tissue, but was absent in 20/23 low- 
grade cervical intraepithelial neoplasia (CIN) specimens and 12/18 high grade CIN. 
This study suggested that the nature of the environment within the epithelium might 
act to limit effective immune response (Mota et al 1999).
It has recently been shown that women with W S  have an increased presence of the 
homozygous form of allele 2 of Interleukin 1 (IL-1) receptor antagonist, which is known 
to be a naturally occurring down regulator of the proinflammatory immune response 
(Jeremias et al 2000).
Regulation of the inflammatory response at skin and mucosal level is a function of 
interactions between inflammatory cells, cytokines and neurokines. The individual 
response to TNFa depends on tissue levels, duration of exposure and presence of
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synergistic cytokines such as IL-1 (3 (Tracey 1994). If other factors involved in this 
response are down regulated, this may affect the expression of TNFa, and other 
inflammatory mediators may be of greater importance in the pathogenesis of W S . 
This explanation may account for our findings that women with VVS appear to express 
less TNFa than the control group.
Other groups have found evidence that VVS is not inflammatory. Although Pyka et al 
(1988) showed a chronic inflammatory infiltrate in biopsies from women with VVS, 
they did not use vestibular tissue from asymptomatic women as a control. However, 
Lundquist et al (1997) found no difference in histomorphologic features when 
vestibular tissue from healthy control patients was compared with vestibular tissue 
from patients with W S .
A year later, immunohistochemical analysis of the neuroendocrine cells of the minor 
vestibular glands found the degree of inflammation in vestibular tissue in women with 
and without VVS was not significantly different (Slone et al 1998).
More recently Bohm-Starke et al (2001) compared expression of inflammatory 
mediators cyclooxygenase 2 and inducible nitric oxide synthase in vestibular tissue 
from 10 women with W S  to 10 healthy controls. Both groups showed low expression 
and there was no difference observed between the groups. Their results indicated no
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active inflammation and they implied that topical corticosteroids had no place in the 
treatment of VVS.
They suggested that their results indicate that the pathophysiological mechanism in 
W S  differs from that of chronic inflammatory diseases, and that the allodynia and 
erythema in the mucosa may be explained by a neuronal mechanism.
It has been proposed that unmyelinated C nociceptor fibres are activated by mediators 
of inflammation, including serotonin, and that protracted activation of the nociceptors 
sensitises "wide dynamic" neurones which produces an abnormal response to light 
touch mechanoreceptors with central sensation of pain (Cox 1995).
We know that from recent studies there appears to be an increase in neural fibres in 
the vestibule in women with W S :
Westrom et al (1998) evaluated nerve fibre density in women with W S . Forty-seven 
patients were assessed and compared to 6 controls, 4 being post mortem samples. 
They found increased nerve fibre proliferation in the samples from women with W S , 
and suggested this would provide a morphological basis for enhanced neuronal firing, 
as suggested in the pain loop theory. Again the comparison was made with interstitial 
cystitis, where similar results were found (Christmas et al 1990).
These findings have been confirmed, showing a significant increase in intraepithelial 
innervation in women with W S  (Bohm-Starke 1998), suggesting focus should be on
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the change in the peripheral innervation as a possible explanation for the symptoms of 
W S . The authors assumed these free nerve endings were nociceptors transmitting 
noxious stimuli, resulting in pain. This assumption was later proved correct when the 
nerve fibres were neurochemically characterised. (Bohm-Starke 1999)
It had previously been shown that the vulval vestibule is rich in neuroendocrine cells 
and that intraepithelial axons are closely applied to these serotonin containing 
neuroendocrine cells. This close association and the presence of substance P 
immunoreactivity in local nerves had been suggested to play a role in the symptoms of 
VVS (Warner et al 1996).
This argument is logical in that we are aware that Substance P causes neurogenic 
inflammation, and there have been reports of increased numbers of Substance P 
positive nerve fibres in the bladders of patients with interstitial cystitis, compared to 
controls (Pang et al 1995). W S  has been associated with interstitial cystitis as there 
is common embryological derivation for the bladder and the vulval vestibule, and 
indeed W S  has been proposed as a generalised disorder of urogenital sinus derived 
endothelium (Fitzpatrick et al 1993).
A study looking for the immunofluorescence of complement activation (previously 
seen in interstitial cystitis), in women with W S , found a similar pattern and suggested 
that Substance P may trigger activation of the complement cascade via endothelial 
damage (Stewart and Berger 1997).
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It is feasible that these women are unable to mount an adequate immune response, 
that then has a modulatory role on the neural pathways of chronic pain. Study of 
patients who do not require surgery to gain improvement in symptoms, but respond to 
conservative management, may clarify whether cytokine expression returned.
Conclusion
The decreased expression of all 3 cytokines in women with W S  compared to normal 
controls was unexpected, as W S  has been postulated as an inflammatory condition. 
However, these findings concur with the decreased expression found in the areas of 
highest algesia in women with W S  as previously described by Foster and Hasday 
(1997).
This argument is also supported by previous evidence that W S  is not inflammatory 
(Bohm-Starke 2001, Slone 1999).
It is not clear whether the apparent lack of TNFa and IL-1 expression in this study is a 
result of the pathogenesis of W S  or a predisposing factor, but as a result of this 
current study, W S  may no longer be regarded as the result of a local inflammatory 
process.
If W S  is not an inflammatory condition, then it is necessary to investigate possible 
causes from a new perspective.
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CHAPTER FIVE - IS VULVAL VESTIBULITIS SYNDROME A 
HORMONAL CONDITION?
Introduction
The possibility of a relationship between VVS and hormonal factors has been 
questioned, although not studied extensively. Two studies have investigated whether 
oral contraceptive pill (OCP) use affects the risk of developing VVS.
In Canada, Bazin et al (1994) performed an exploratory case control study to evaluate 
the association of potential risk factors with occurrence of W S . Fifty-seven women 
fulfilling Friedrich's criteria were recruited and compared to 173 controls without 
dyspareunia. OCP use showed some association with relative risk (RR) of developing 
W S . Compared to women who had never used the OCP, former and current users 
had RR of developing W S  of 4.6 and 6.8  respectively. Early use of the OCP 
increased the risk further, with women who had used the OCP before the age of 17 
having a RR of 11.0 (95% confidence intervals (Cl) 1 .3 -  97.1) compared to women 
who had never used the OCP. Duration of use did not appear to affect relative risks. 
Early menarche was also associated with increased risk (RR= 1.8 Cl 0.8 -  4.0).
The authors suggested that factors occurring early in reproductive life are relevant and 
these may well be hormonal. A possible explanation was offered: the oral 
contraceptive pill has an effect on glandular components and vestibular mucus 
secretion, which play a role in coital lubrication. They therefore proposed that mucus 
protects the vestibular epithelium against physiological secretions and that alterations 
in this protection lead to a chronic irritant effect, which leads to dyspareunia.
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A further epidemiological case control study also found an association with OCP use 
(Sjoberg et al 1997). Thirty-two women were compared to 17 healthy controls, and it 
was found that cases of VVS had used the OCP for a significantly longer period of 
time.
The authors suggested that the hypothesis proposed by Bazin et al was contradictory, 
considering most patients improve with vestibulectomy, which removes the glands. 
They suggested that if these glands were important then it would be expected that the 
condition would worsen if the glands were removed.
The same authors had previously demonstrated down regulation of oestrogen 
receptors (ER) by the OCP (Sjoberg et al 1989). They proposed that prolonged use, 
or use early in life, leads to increased down regulation of ER and lower levels of ER 
lead to the vestibular epithelium becoming thin and fragile and therefore irritated by 
the acidic vaginal pH.
Two authors have described the use of topical oestrogen cream as treatment for W S  
with some success (Bazin et al 1995, Willems 1999).
Bazin et al performed a randomised double-blind placebo controlled study using 
vaginal oestrogen cream. Sixty-six percent of patients improved compared to 48% in 
the placebo arm. This was not a statistically significant result; however, a statistically 
significant decrease in the erythema of the gland openings was noticed.
The study by Willems used a combination of oestrogen cream, biofeedback and low 
oxalate diet and so it is not possible to ascertain which treatment was the effective
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component. Unfortunately, neither author proposed a mechanism linking VVS and 
oestrogen.
In the specialist Vulval Clinic at the Royal Free Hospital it was noticed anecdotally that 
many of the patients with VVS had hormonal factors that appeared to affect their 
symptoms. A proportion of women had been diagnosed with polycystic ovaries, 
following investigation for menstrual irregularities, with others reporting that 
pregnancy, or commencing or ceasing the combined OCP altered their symptoms. 
Women who had managed to become pregnant reported changes in the severity of 
their condition connected to breast-feeding, a known hypo-oestrogenised state.
In view of the apparent changes in symptoms with potential changes in oestrogen 
levels, we considered whether oestrogen could be implicated in the aetiology of W S. 
The results presented later in this chapter, of serum oestradiol levels, led us to 
investigate oestrogen effects at the cellular level within the vulva.
Oestrogen can have an immunomodulatory effect, as it can stimulate antibody 
response but inhibit T cell mediated inflammation (Jossefson et al 1992). It has been 
shown that if markers of inflammation are measured before and after oophorectomy 
they rise. Equally, replacement of oestrogen post surgery corresponds to a reduction 
in levels of inflammatory markers (Pacifici et al 1991).
In women who are taking the OCP, endogenous oestradiol is suppressed (Gillmer et 
al 1980). Equally during the pill free interval serum oestradiol rises and by the seventh
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day of the cycle some women have similar oestradiol concentrations to untreated 
women in the early follicular phase of a natural menstrual cycle (Cohen 1979). This 
would concur with a study performed at the Royal Free Hospital looking at follicular 
development in the pill free interval, as increasing oestradiol is the result of follicular 
development. One hundred and twenty women were scanned at the end of the pill 
free interval and 23% were found to have significant follicular development that could 
lead to ovulation (Tayob 1990).
On the basis of the above data, I postulated that women with VVS exhibit a degree of 
abnormality either of serum oestrogen levels or oestrogen receptor expression within 
the vestibule, effectively making them unresponsive to local circulating oestrogen, so 
that inflammation is not suppressed
O e s tro g e n  re c e p to rs
Discovered by Elwood Jensen in 1958 the oestrogen receptor (ER) is a ligand 
activated transcription factor that mediates the effects of the steroid hormone 17-beta- 
oestradiol in both males and females. It has the characteristic structure of a member 
of the nuclear hormone receptor superfamily. It has been shown that oestrogen 
receptors are present in both the vagina and vulva, using both biochemical (ELISA) 
and immunohistochemical methods (Garau et al 1986, MacLean et al 1990). Using a 
rat monoclonal antibody against human ER, in frozen tissue with a peroxidase- 
antiperoxidase technique, MacLean et al (1990) demonstrated ER expression in 
epidermal keratinocytes and dermal fibroblasts of the vulva and perineum. This
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expression was at a much lower frequency and intensity of staining than that seen in 
the vagina. They were unable to detect any ER expression in the vulval stroma. As 
the concentration of oestrogen receptors decreases from the vagina out through the 
vestibular area to the vulval skin, it may be expected that the normal vestibule would 
express oestrogen receptors.
Similar results were later obtained by the same group, using a standard streptavidin- 
biotin technique on frozen sections, again using a rat monoclonal antibody against 
human ER (Hodgins et 1998). Semi quantitative analysis, using ER expression from 2 
random fields, confirmed a significant decline in epidermal and fibroblast ER 
expression from the vagina out towards the vulva and perineum. The group did not 
find ER associated with blood vessels, implying that oestrogen does not have a role to 
play in the vasculature of the vulva. Distribution of oestrogen receptors in both the 
vulva and vagina did not differ between pre and postmenopausal women. 
Progesterone receptors did not appear to be present in the vulva, although they were 
found in the vagina.
Initially it was thought there was only one oestrogen receptor but in recent years a 
second subtype of receptor has been discovered (ERP) and so the original oestrogen 
receptor is now known as ERa (Paech et al 1997). The work demonstrating the 
presence of ER in the vulva used an antibody that does not cross react with ER(3, and 
so it is assumed that ER in the vulva is of the ERa subtype.
In view of the fact that some of the patients with W S  seen in the Vulval Clinic 
appeared to respond to topical oestrogen, it was decided to conduct two studies: the
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first to investigate ER expression in patients with W S , compared to normal controls, 
and the second to see if there was any relationship between ER expression and 
response to topical oestrogen therapy.
Study 1 -  Investigation of ER expression in W S  
M a te ria ls  a n d  M e th o d
Tissue and serum samples
Serum oestradiol levels in a group of women with W S  (n=105) were measured and 
compared to levels in a group of normal controls (n=57). The normal controls were 
patients without any vulval symptoms who were having unrelated surgery. The mean 
age of the W S  patients was 34.6 (range 22 -  53) and the mean age of the control 
group was 32.3 (range 20 -  46). The serum samples were linked in both groups with 
the time of the subject’s menstrual cycle. Of the 105 blood samples taken from 
women with Vulval Vestibulitis Syndrome, 73 were not using hormonal contraception, 
and 8 of these were postmenopausal.
57 control samples were taken from premenopausal women, who were not using 
hormonal contraception.
Serum oestradiol ELISA assays were performed on all samples and the results of the 
2 groups compared.
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Tissue was obtained from women with a diagnosis of VVS (n=30) who fulfilled 
Friedrich's triad. This was either from women whom were undergoing vestibulectomy 
or from punch biopsies taken in the vulval outpatient clinic.
The directed biopsies were taken under colposcopic guidance from the vulval 
vestibule over the area of one of the entrances to the lesser vestibular glands. In 
patients undergoing vestibulectomy, the whole of the vulval vestibule was removed 
(Marinoff and Turner 1991).
Following ethical approval, control tissue was obtained from patients (n=20) 
undergoing unrelated gynaecological surgery from whom permission had been 
granted to remove a 4mm punch biopsy from the vulval vestibule whilst under general 
anaesthetic. Outpatient biopsies were taken under local anaesthetic using 2ml of 
Citanest and Octapressin (Astra). Punch biopsies were obtained using a Stiefel punch 
with a diameter of 4mm.
All of these women were asymptomatic and not taking hormonal contraception. Six of 
the study group were currently using the OCP.
All of the control group and all but one of the study group were premenopausal. In 
both groups all the women were Caucasian and the controls were selected to age 
match the study group.
Haemostasis was obtained with either silver nitrate sticks or Monsel's solution.
The tissue was placed in neutral-buffered formalin and then paraffin wax-embedded. 
Five micrometer sections were cut and one section was stained with Haematoxylin 
and Eosin (H&E) and the histopathology reviewed by a consultant gynaecological 
pathologist, to exclude other vulval pathology.
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All sections were placed on 3-aminopropyltriethoxysilane-coated glass slides.
Positive control tissue for ERa staining was from a known ERa positive breast cancer. 
Positive control tissue for progesterone receptor (PR) staining was from a known PR 
positive breast cancer. The antibodies used are summarised in Table 5.1
Table 5.1 ERa and progesterone antibodies
Receptor Antibody Dilution
ERa
Clone ID5
Cat No. M7047, DAKO 
Cambridgeshire, UK
1:50
Progesterone
Clone 1A6
Cat No. NCL-PGR, Novocastra, 
Newcastle upon Tyne, UK
1:200
Antigen retrieval was performed by microwaving the sections for 20 minutes in 10mM 
sodium citrate buffer (pH 6.0). Primary antibody was then incubated for 1 hour at 
room temperature, followed by the biotin linked secondary. Negative controls had the 
primary antibody omitted. Stain was detected using streptavidin-biotin horseradish 
peroxidase complex (Dako, K0492) and 3,3’- diaminobenzidine. The sections were 
counterstained with Mayer’s Haemalum (Merck, Lutterworth, Leics. UK) to define the 
cell nucleus and analysed under light microscopy.
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Nuclei that were positive for ERa or PR stained brown and nuclei that were negative 
for ERa or PR stained blue.
The full immunohistochemical protocol is shown in Appendix 2.
Scoring Methods
Two methods for quantifying the number of oestrogen receptors present were studied. 
The sections were analysed independently by 3 observers. Concurrence of opinion 
was defined as less than 5% variation in result.
If there was discrepancy of more than 5% in the results, the slides were reviewed by 
all observers and consensus of opinion obtained.
The first method was to take two random fields under a magnification of x200 and 
count the number of nuclei that stained positive in both the basal epidermis and the 
dermis, and express them as a percentage.
The intensity of the staining was also assessed and graded, with 1 being the weakest 
intensity and 4 being the strongest. These two numbers were then multiplied to give a 
final score for each field. The grading of intensity of staining is subjective, although 
previous studies have shown it to be reproducible (Hodgins et al 1998). Strict 
protocols related to concentration of solutions and timing of steps in the staining 
protocols were adhered to for each batch of slides processed.
In the second method, the whole sample was assessed. A field measuring scale was 
inserted into the eyepiece of the microscope and the total length of the epidermis was
152
measured. Then the length of epidermis with positive staining nuclei was measured. 
Therefore it was possible to calculate the number of positive staining epidermal nuclei 
in each section as a percentage of the total basal layer, to produce a staining index for 
each section. This was performed for both ER and PR. These indices were then put 
into groups (e.g. 0 -  10%, 10 -  2 0 % etc.).
This second method was found to be more accurate, as it assessed the entire 
specimen, and therefore was used to calculate the results.
Statistics
Statistical analysis was performed using a Minitab Stastistics package for Windows. 
Data were analysed using Chi Squared or Mann Whitney U tests.
Results 
S e ru m  o e s tra d io I
Six of the fifty-seven control samples (10.5%) had serum oestradiol levels lower than 
the reference ranges for that point in the menstrual cycle.
Twenty six (25%) of the patients with W S  had abnormally low oestradiol levels for 
that point in their menstrual cycles.
However, if the patients who were taking hormonal contraception, and therefore 
suppressing their endogenous levels of oestradiol, were excluded then only 9 samples
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(8.6%) were outside the reference ranges. This is not statistically significant 
difference compared to the control group, using a Chi-Squared test.
The serum oestradiol results from women not taking hormonal contraception, are 
shown in Table 5.2 and represented graphically in Fig 5.1
Fig 5.1 Serum oestradiol of VVS and controls
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ERa Expression
In the control group all the tissue samples exhibited ERa expression, with the majority 
showing more than 50% positive basal cells. In the group with W S , 50% of the tissue 
samples did not exhibit any expression of ERa. Equally in the VVS tissue that did 
show ERa expression, this was confined to fewer basal cells, compared to the 
controls.
Fig.5.2 shows the differences in expression of oestrogen receptors between the group 
of women with VVS and the control group. Fig 5.3 and 5.4 show ER expression in 
W S  and control tissue.
There was no significant difference in the results, including the presence of skip 
lesions, (where a significant length of basal nuclei failed to demonstrate any ER 
staining within a length of positively staining basal nuclei) in the women with VVS, 
regardless of whether the tissue obtained had been by punch biopsy or by 
vestibulectomy. There does not appear to be correlation between OCP use and ER 
expression although this finding is not significant as the numbers are so small (n=6 ).
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Fig 5.2 ERa expression in VVS and controls
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Analysed using a Chi Squared test, the difference between cases and controls was 
statistically significant (p=0.0003). The staining of the oestrogen receptors was 
predominantly in the basal layer of the epidermis, although some stromal staining was 
evident in some of the samples in both groups.
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Fig 5.3 Vestibular tissue showing no ER expression
Fig 5.4 Vestibular tissue showing ER expression
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The results obtained using the two different scoring methods are shown in Tables 5.2 - 
5.4.
Table 5.2 Results: ER expression in control tissue in 2 random fields
Control F1 E 
Int
F1 E % F1 D 
Int
F1 D % F2E
Int
F2 E % F2 D 
Int
F2 D %
1 3 100 0 0 3 100 0 0
2 1 50 1 20 1 50 1 5
3 2 70 0 0 2 50 1 10
4 1 30 0 0 1 25 0 0
5 2 100 2 <5 3 100 0 0
6 1 5 1 10 4 100 0 0
7 3 40 0 0 3 100 1 10
8 2 75 0 0 3 85 2 <5
9 3 100 0 0 4 100 2 <5
10 2 100 1 5 4 100 2 5
11 2 80 1 <5 2 50 0 0
12 4 100 2 <5 3 75 0 0
13 1 40 1 50 2 75 0 0
14 4 80 1 5 4 10 2 10
15 4 100 3 10 4 100 2 20
16 4 100 0 0 3 100 0 0
17 4 100 2 15 4 100 0 0
18 3 100 0 0 2 80 0 0
19 1 100 0 0 1 100 0 0
20 3 100 0 0 3 100 1 <5
21 4 100 0 0 4 100 1 10
Key:
F1 = Random Field 1 F2 = Random Field 2
E Int = Epidermal Intensity E % = Epidermal percentage staining positive
D Int = Dermal Intensity D % = Dermal percentage staining positive
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Table 5.3 Results: ER expression in VVS tissue in 2 random fields
SAMPLE F1 E 
Int
F1 E % F1 D 
Int
F1 D % F2E
Int
F2 E % F2 D 
Int
F2 D %
979632 4 75 4 20 4 50 3 25
9714579 2 60 0 0 1 50 1 30
95436 0 0 0 0 0 0 0 0
975839 3 100 2 70 3 95 2 80
921212 0 0 3 95 0 0 4 95
190697b 1 0 0 0 0 0 3 10
946844 1 10 0 0 0 0 0 0
956595 3 50 0 0 2 30 0 0
943708 3 10 2 5 1 20 2 30
961552 0 0 0 0 1 10 0 0
94419 4 90 1 0 3 60 0 0
968886 0 0 0 0 0 0 0 0
953949 2 85 0 0 1 80 0 0
95394 2 85 0 0 2 90 0 0
94861 3 80 0 0 0 0 0 0
943709 4 25 3 50 4 20 0 0
9610453 4 10 2 10 4 70 0 0
963371 0 0 0 0 0 0 0 0
975954 0 0 0 0 0 0 0 0
976017 2 20 1 10 1 30 0 0
978704 1 10 0 0 0 0 0 0
974024 0 0 0 0 0 0 0 0
190697 0 0 0 0 0 0 0 0
190697c 0 0 0 0 0 0 0 0
9711579 1 20 0 0 1 10 0 0
9713276 2 30 1 50 1 10 0 0
971668 0 0 0 0 0 0 1 50
94196 0 0 0 0 0 0 0 0
9712432 1 60 0 0 1 50 0 0
978868 0 0 0 0 0 0 0 0
97474 0 0 0 0 0 0 0 0
9712093 3 60 0 0 4 60 0 0
954773 0 0 0 0
975629 0 0 0 0 2 10 0 0
973858 0 0 0 0 0 0 0 0
916353 2 10 0 0 3 50 0 0
972740 4 80 0 0 4 50 0 0
975839 4 10 0 0 4 10 0 0
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Table 5.4 Results: ER expression as percentage of total length of sample
SUBJECT SAMPLE RESULT 
(% +VE)
CONTROL SAMPLE RESULT
(%+VE)
975954 P 0 1 P 90
976017 V 45 2 P 60
921212 V 0 3 P 70
94419 V 100 4 P 25
978704 p 10 5 P 100
971668 V 0 6 P 75
963371 V 0 7 P 78
974024 V 0 8 P 80
946844 V 0 9 P 100
94861 V 0 10 P 97
943709 V 92 11 P 75
961552 V 0 12 P 75
956595 V 37 13 P 67
972740 V 50 14 P 53
190697 p 0 15 P 100
190697b p 0 16 P 100
190697c p 55 17 P 100
979632 p 66 18 P 95
9711579 p 25 19 P 100
943708 V 0 20 P 100
954773 V 30 21 P 100
916353 V 42
9712093 V 58
975629 p 50
9713276 p 100
953949 V 10
973858 p 0
9712432 p 70
94169 V 100
978868 V 0
97474 V 0
9610453 p 100
968886 p 0
95436 V 0
9714579 p 0
975839 V 95
P = Punch biopsy 
V = Vestibulectomy specimen
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A phenomenon seen in the tissue samples of the group with Vulval Vestibulitis 
Syndrome but not in the control group, was the appearance of apparent “skip lesions” 
in the staining of the basal layer. ER_ expression was found in patches, with negative 
staining areas in between. It was noted that often there was an area of lymphocytic 
infiltration below the negative areas, indicating an area of chronic inflammation. An 
example of a skip lesion is shown in Fig.5.5.
Fig 5.5 A “skip lesion'
PR Expression
No PR expression was demonstrated in the vestibular samples from either the control 
group or from the women with Vulval Vestibulitis Syndrome.
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Discussion
There has been little work examining VVS at a cellular level. The majority of 
investigations have concentrated on the histopathology of this condition, and have 
remained inconclusive. Two recent studies have attempted to explore VVS at this 
level by analysing inflammatory markers associated with this condition (Foster et al 
1997, Jeremias et al 2000), but serum oestradiol or tissue oestrogen receptor 
expression have never been investigated. Inflammatory markers and VVS are 
discussed in greater detail in Chapter 4.
S e ru m  o e s tra d io l
The fact that there is no correlation between serum oestradiol and W S  is not 
surprising. Although there have been reports in the literature that some women find 
their symptoms to be cyclical, the definition of W S  implies that the symptoms are 
constant, exacerbated at each attempt at vaginal penetration. The women with low 
serum oestradiol did not report any menopausal symptoms in either the control or 
study groups. This is not surprising, as previously discussed, women taking the oral 
contraceptive pill have their endogenous oestradiol suppressed, and they do not suffer 
with menopausal symptoms. The results here reflect endogenous serum oestradiol 
levels, as there is no cross reactivity between ethinyloestradiol and oestradiol 17p 
(personal communication, Professor Back, Department of Pharmacology and Clinical 
Therapeutics, University of Liverpool).
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Although mainly affecting premenopausal women we recognise that W S  is seen, 
although uncommonly, in older postmenopausal women and this group is represented 
in our cohort. Equally, in patients who report improvement in their condition when 
pregnant, we cannot conclude that increased serum oestrogen is responsible.
In view of the lack of systemic symptoms, it is more logical that any hormonal 
connection with VVS is more likely to be at a local level. We know that the signs of 
W S  are elicited in very specific sites with the rest of the vulva not involved.
P ro g e s te ro n e  re c e p to rs
The lack of PR expression in the vestibule concurs with previous work showing PR 
expression in the vagina but not in the vulva (Hodgins et al 1998).
Embryologically the vestibule and the vulva are derived from the same origin, the 
urogenital sinus. Therefore it is not surprising that vestibular tissue, as well as vulval 
tissue, does not express PR, whereas vaginal tissue, which is Mullerian in origin, does 
express PR.
O e s tro g e n  re c e p to rs
The results from this part of the study are possibly of greater relevance to this 
condition.
Two methods for quantifying the number of oestrogen receptors present were initially 
used. The first was the use of random fields and grading of number of receptors and 
intensity of nuclear staining. The second was to measure the whole length of the 
sample and to calculate the percentage of positive cells in the basal layer. The
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disadvantage of the first method was that on some of the samples there appeared to 
be 'skip lesions’ in which there was a sudden cut off between positive and negative 
nuclei. Thus, if two random fields were selected it was possible to obtain a negative 
result by chance, from a sample that was actually predominantly positive.
The second method was chosen as the preferred method of assessment in this study 
as it removed the possibility of choosing at random an area that was not 
representative of the whole sample. It allowed assessment of the entire section of the 
slide and allowed skip lesions to be recorded.
Given the marked difference in ERa expression between the 2 groups, and decreased 
expression in W S  patients, this initial study has raised a variety of questions to be 
investigated further. We do not know if the skip lesions can be related to areas of 
inflammation, thus supporting the theory that inflammation can be suppressed by the 
use of oestrogen, but in view of the previous chapter's findings, this may not be the 
case. This could perhaps predict the success of treatment.
Both topical steroid preparations and topical oestrogen are widely used as medical 
management of W S  (Bazin et al 1995, Willems 1999, Sonnex 1999). However if a 
patient does not have local oestrogen receptors, then topical oestrogen will be 
ineffective.
As to why some women respond to local topical oestrogen remains unclear. Certainly 
these women are not menopausal but it appears their endogenous oestrogen is
164
insufficient. I believe there is a local problem with the tissue and therefore circulating 
hormones are not relevant.
It has previously been shown that the OCP can downregulate ER in the vulva (Sjoberg 
1989), although this was not seen in my study. We also know that the OCP produces 
a hypo-oestrogenised state, as previously discussed. Could it then be possible that 
high dose local oestrogen could upregulate the ER and improve patient’s symptoms? 
This would be an interesting future study to investigate these effects.
Another possibility that has been proposed is that the tissues are fragile due to 
insufficient oestrogen and replacing the oestrogen improves the quality of the tissues 
(Bazin 1994), and this could be explained by the mechanism described above.
A third explanation is offered by Bohm-Starke et al (2004), who demonstrated that 
women on the OCP have a lower mechanical pain threshold and that oestrogen is a 
potent pain modulator, therefore it is possible that topical oestrogen somehow 
modulates pain perception and reduces the allodynia experienced. The same group 
had previously demonstrated increased nociceptor sensitisation (Bohm-Starke et al 
2001) and it is possible that oestrogen could modulate this sensitisation.
Subsets of VVS have been proposed in the past (Goetsch 1991) but these have 
referred to onset of symptoms rather than different aetiological factors. If there were a 
subset of women with W S  who have abnormal oestrogen receptor expression, then 
this would explain why not all patients would respond to topical medical therapy and 
therefore require surgical intervention.
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Previous medical treatment may down regulate ER expression and further controlled 
study is needed. In our population, medical treatment had been used for some of the 
patients previously, with some patients receiving multiple treatments before referral. 
The majority of the specimens obtained as outpatient punch biopsies had used topical 
steroids previously, but had been treatment free prior to biopsy. The vestibulectomy 
specimens were from women who had not responded to multiple medical treatments, 
including topical steroids and oestrogen, but all patients had ceased medical treatment 
several months prior to surgery. As none of the group was undergoing active 
treatment at the time the biopsies were taken, the lack of ER expression seen in this 
study probably cannot be explained by the theory of down regulation.
Conclusion
An understanding of the oestrogen receptor expression in women with VVS may allow 
us to predict which patients are likely to respond to specific treatments, allowing the 
clinician to improve management.
Using this theory I then performed a further analysis to investigate response to 
treatment and whether it correlated with ER expression.
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Study 2 - Treatment response and ER status
M a te ria ls  a n d  m e th o d s
The 30 women with VVS from whom the biopsies had been taken were followed 
during the study to assess ultimate response to treatment.
Response to treatment was assessed subjectively by patient opinion and measured 
objectively with the algesiometer.
Successful treatment was defined as the treatment to which the patient responded to 
the point they were able to have intercourse, which led to their discharge from the 
clinic.
The protocol for treatment of W S  at the Royal Free at this time is summarised below:
Examination and swabs were performed to exclude other conditions.
Initial treatment was Trimovate ® cream (clobetasone butyrate 0.05%, oxytetracycline 
3%, Nystatin 100 OOOunits/g) applied nightly for 8 weeks to the vestibule. In order for 
accurate treatment the vestibule was shown to the patient by use of a colposcope and 
a closed circuit television link to a monitor. This enabled the patient to identify the 
area that needed treatment.
At the first clinic visit the patient was counselled about her diagnosis. Difficulties in 
recognition and treatment was discussed, as often the women had seen multiple 
clinicians and offered multiple treatments. The treatment protocol was explained in
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detail, emphasising that relatively few women eventually required surgery. General 
advice was given about underwear, toiletries and contraception, to minimise potential 
allergens during treatment.
Although there was not a psychosexual counsellor attached to the clinic, patients were 
advised this was available within the hospital if required and the opportunity for the 
patient’s partner to attend the clinic was offered.
Written information was given to take home, about vulval vestibulitis syndrome and 
support groups, such as the Vulval Pain Society were discussed.
The patient was provided with the telephone number of the investigator, should they 
wish to contact the clinic.
Patients were reviewed after 2 - 3  months. If there had been little or no response to 
steroids, then a course of topical oestrogen cream (Premarin ®) applied nightly for 8 
weeks was prescribed.
Vestibulectomy was performed only for women who had failed all medical treatment 
and constituted less than 10% of all new referrals of women with W S.
Vestbulectomy was performed under a general anaesthetic. The vulval vestibule was 
identified and the margins marked with a carbon dioxide laser, extending anteriorly in 
a horseshoe shape to include both paraurethral glands, and posteriorly to the 
fourchette at the outer margin and the hymenal ring at the inner margin. The vestibule 
was then removed, either by sharp dissection, or using the laser to a depth of 3 -
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5mm. The vagina was then undermined and mobilised to cover the defect. 
Haemostasis was achieved and the vagina sutured to the vulva using interrupted 2/0 
undyed vicryl®. Local anaesthetic was infiltrated and the vulva covered with a 
Gelonet® dressing and a urethral catheter inserted overnight. Most patients were 
discharged on day 2.
Unfortunately some of the earlier vestibulectomy specimens were retrieved from 
archival tissue. These patients had not benefited from sequential treatment, or had 
been referred specifically for surgery from other units and this accounts for the larger 
than expected proportion of surgical samples compared to outpatient punch biopsies.
Case note review
To confirm our experience that few women with W S  ultimately are treated by surgery, 
the treatment and outcome of all patients seen during the study period of 1997 -  1999 
were reviewed. All case notes and research databases were reviewed to establish 
outcome data. Where data were not available, the patients were contacted to 
establish outcome.
R e s u lts
Of the 30 women who had biopsies, 1 went elsewhere for treatment and so no follow 
up data is available. Out of the remaining 29 patients, 3 responded to Trimovate, 7 
responded to Premarin and 19 responded to surgery. The ER status of each of these 
groups was analysed and shown in Table 5.6 and summarised in Table 5.7. Six of the
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samples were from archived tissue and therefore had not been through the sequential 
treatment protocol, and so these were excluded from the analysis.
Table 5.5 ER status and treatment response
SUBJECT ER status Treatment responded 
to
975954 Negative Premarin
973858 Negative Trimovate
921212 Negative Surgery
971668 Negative Surgery
963371 Negative Surgery
946844 Negative Surgery
94861 Negative Surgery
943708 Negative Surgery
978868 Negative Surgery
97474 Negative Surgery
968886 Negative Surgery
95436 Negative Surgery
9714579 Positive Premarin
976017 Positive Premarin
978704 Positive Premarin
9711579 Positive Premarin
9713276 Positive Premarin
9712432 Positive Premarin
9610453 Positive Trimovate
979632 Positive Trimovate
975839 Positive Surgery
943709 Positive Surgery
956595 Positive Surgery
94419 Positive Surgery
954773 Positive Surgery
9712093 Positive Surgery
975629 Positive Surgery
953949 Positive Surgery
94169 Positive Surgery
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Table 5.6 Summary of ER status and response to treatment
TREATMENT PREMARIN (n=7) TRIMOVATE (n=3) SURGERY (n=13)
ERa POSITIVE
(n=11)
6 2 3
ERa NEGATIVE
(n=12)
1 1 10
This shows that in the group that did not express ERa, 83% (n=10) responded to 
surgery and 17% (n=2) responded to medical treatment, one responding to topical 
steroid and one responding to topical oestrogen.
In the group that did express ERa, 27% (n=3) responded to surgery and 73% (n=8) 
responded to medical treatment, two responding to topical steroid and 6 responding to 
topical oestrogen.
This concurs with our experience that the minority of patients will require a 
vestibulectomy to treat their condition.
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Patients discharged and response to treatment
During this period 109 new patients were seen with a diagnosis of vulval vestibulitis 
syndrome. The mean number of visits to the clinic was 3. Seventy patients had been 
discharged from the clinic and 39 had not been discharged.
Sixty-two of the patients said they had responded to treatment. When asked about 
their symptoms at their last visit to the clinic, 58 said that intercourse was pain free 
and 4 said that intercourse was possible but associated with a minor degree of pain.
The treatment the patients responded to is shown in Table 5.8.
Table 5.7 Treatment Response
Treatment Number of patients
Trimovate 31
Premarin 14
Surgery 13
Other 4
The treatments in the “other” category were tricyclic antidepressants (n=1), Chinese 
herbs, which on further investigation were found to contain oestrogen (n=1) and low 
oxalate diet (n=2).
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Surgery
From the 109 patients presented with vulval vestibulitis syndrome 15 were offered 
surgery, as they had not responded to medical treatment. Thirteen had improved 
following vestibulectomy, 1 declined surgery and one patient’s symptoms worsened 
following surgery. This patient was a tertiary referral from another unit who had 
declined sequential medical treatment and only wanted surgery. She later responded 
to topical oestrogen therapy.
Patients not discharged
Of the 39 patients not discharged from clinic, 22 were still receiving treatment, 15 had 
not attended their follow up appointment and 2 had not attended follow up twice.
The patients who had not attended their follow up appointments who were contactable 
by telephone were asked why they had not attended follow up appointments. Their 
reasons are summarised in Table 5.9. I was unable to contact the 2 patients who had 
not attended twice.
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Table 5.8 Reasons for not attending follow up
Reason not attended follow up Number of patients
Improved with treatment given 5
Left country 3
Declined research participation 1
Declined surgery 1
Attended other vulval clinic 3
Requested endocrine referral 1
Pregnant 1
Assessment of response to Premarin
Response to treatment was assessed in two ways, as previously described in Chapter
2. Patient’s subjective perception of whether their symptoms had improved or 
worsened with treatment was recorded along with their ability to have sexual 
intercourse. Objective assessment of vestibular tenderness was assessed using the 
algesiometer, which we have previously shown correlates well with patient 
symptomatology.
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Comparisons of the algesiometer readings before and after treatment with Premarin 
were made. The overall median algesiometer scores for the treatment group were 
calculated and compared to the scores recorded at the 1st visit to the clinic, prior to 
treatment.
Statistical analysis was performed using a Minitab Stastistics package for Windows. 
Non parametric data were analysed with the Mann- Whitney U test.
Table 5.9 Comparison of algesiometer scores: 1st visit and after Premarin
Comparison Mean scores P value
1st visit / Premarin (n=14) 5 .0 -18 .0 0.00008
This result is highly significant and shows there was a genuine improvement in 
vestibular tenderness in the groups using Premarin.
If subdivided further to look at the group that was discharged following successful 
responses to treatment, again the results are significant: these results are shown in 
Table 5.10.
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Table 5.10 Premarin responders: Comparison of algesiometer scores before and after treatment
Comparison Mean scores P value
1st visit / Trimovate 1 2 - 9 0.88
1st visit / Premarin 7 - 1 5 0.005
T rimovate/Premarin 6 - 1 9 0.003
(N=14)
This shows there was genuine significant response to treatment with Premarin and 
that the patients who did respond to Premarin did not respond to Trimovate.
Discussion
These results are encouraging, as it appears that there if the ER status of a patient is 
known, then it may help in predicting what treatment they may respond to.
Although topical oestrogen has been reported as being successful in some patients 
with VVS (Sonnex 1999, Willems 1999) until now there has not been any logical basis 
for its use.
It is also encouraging that most women will respond to treatment, although finding the 
correct approach can take time and this is particularly important in this group of 
women, who often have been searching for a cure for a considerable period of time. 
These data also highlight the need for logical sequential medical treatment, prior to
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surgical intervention, which may not be necessary. This should be reiterated to 
patients, who may have attended a tertiary referral unit purely for a surgical opinion 
and may not be keen to participate in any further medical treatment, as the multiple 
treatments they have already tried elsewhere have been unsuccessful.
It is easy as a clinician to assume that if a patient does not return to the clinic it is 
because she is cured, and the follow up data in this study represent a more accurate 
picture of the reasons for non attendance, although in this case one third of the 
patients lost to follow up had actually improved, and therefore had not thought it 
necessary to return.
Conclusion
Treatment response to topical oestrogen is likely if the patient does express ERa, and 
these patients are unlikely to respond to topical steroids. This may make decision 
making when tailoring treatment to a patients needs easier, but the need for larger 
prospective studies and follow up is recognised.
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CHAPTER SIX - DISCUSSION
VVS remains a frustrating and complex problem, both for the clinician trying to treat 
these women and the women who suffer with it. The lack of a definite pathological 
diagnosis, or a logical treatment algorithm means that frequently patient and clinician 
are left with uncertainty.
This thesis has attempted to clarify some of the previously uninvestigated areas of this 
complex condition, and although some questions have been answered, many more 
have been raised.
The objectives of this thesis were:
1. To review the current knowledge in the literature about W S.
2. To define the epidemiological characteristics of our cohort of women and compare 
these to existing data.
3. To objectively quantify the pain experienced by women with VVS.
4. To explore whether VVS is an inflammatory condition.
5. To explore whether W S  has a hormonal component.
The data from my cohort are consistent with many characteristics common to other 
cohorts worldwide.
It is interesting that most women can identify a precipitating factor, and more work is 
needed to see what acts as a trigger to cause severe problems in a previously healthy
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woman. It seems unlikely that vulvovaginal candidiasis is the cause, although over a 
quarter of the women believed such an episode precipitated their symptoms.
Although my cohort was not compared to a control group, it was not the intention of 
this study to compare the epidemiological differences between women with VVS and 
the normal population. This has been done in other studies and the concern of this 
thesis was whether this cohort compared to those elsewhere in the world, and whether 
environmental or cultural factors had any role. This does not appear to be the case, 
as the data contained in this thesis regarding epidemiological characteristics are 
comparable with groups from the US (Goetsch 1991) and Sweden (Sjoberg et al 
1997). Again the most striking feature is that this condition does not appear to affect 
women who are not Caucasian. Although it may be expected that a cohort from 
Sweden would be mainly white, this is not the case in London. The question of 
genetic predisposition is certainly raised, and warrants further investigation.
This study has successfully quantified the tenderness experienced by women with 
VVS.
The algesiometer has proved to be a valuable asset, both in assessment of the 
condition, and monitoring progress with treatment. It is non-invasive, easy to use, and 
provides a definitive value for the tenderness experienced. As previously discussed in 
Chapter 2, Q-tip tenderness is very subjective, and user dependent. The algesiometer
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has provided a reproducible method of assessment, which removes bias, both 
between clinicians and between different examinations.
The patients find it very acceptable, and it's use enabled them to see improvement in 
a very real way, providing an excellent method of biofeedback.
It also proved to be a robust research tool, and enabled comparison of treatment 
modalities, which would not have been possible with subjective assessment.
The part of this thesis investigating whether W S  is an inflammatory condition has 
produced significant results, and added to the growing evidence that VVS is not the 
result of chronic inflammation and hence should not be treated as such. The 
implication, as a result of this evidence, is that W S  is not an “itis” and the renaming of 
the condition by the ISSVD in 2003 to localized provoked vulvodynia, may be more 
appropriate.
We do not know whether the decreased expression of the cytokines found in the 
vestibular tissue of women with W S  is the cause of the condition, or the result of the 
pathological process. It is unlikely to be causative, as the physical appearance of the 
vestibular glands is that usually seen with inflammation. If, however we are to assume 
that the erythema seen is not a result of an inflammatory process, but the result of 
increased blood flow to the area, due to neoangiogenesis, this could be explained.
Laser Doppler Perfusion Imaging (LDPI) has previously been used by a group at the 
Royal Free Hospital (Saravanamuthu et al) to investigate blood flow in the vulva. At
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the start of this project, I did attempt to assess vestibular blood flow, using this 
technique, but no results were obtained due to the technical difficulties in accessing 
the vestibular area, without having to stretch adjacent tissues. The previous LDPI 
studies had concentrated on the labia majora and minora, which obviously are easier 
to access.
Future studies of angiogenesis including assessment of vascular endothelial growth 
factor (VEGF) would be useful, as it would be expected that these would be 
overexpressed in the vestibular area of women with W S.
It has been shown there is increased innervation in the vestibule of symptomatic 
women (Bohm-Starke et al 1998, Westrom et al 1998), and it may be there is 
increased blood vessel formation associated with this neural proliferation.
The concept of increased innervation is interesting, as it gives an explanation for the 
hyperalgesia found in W S . It also would explain why vestibulectomy appears to be 
successful, as the areas of neuronal proliferation are removed. This would provide the 
explanation for the need for surgery in some of these women, which previously had 
not seemed logical as to why removing apparently normal tissue helped to alleviate 
symptoms.
It is of course feasible that low levels of cytokines are the result of an inability to mount 
an immune response, but again this would have to be a local phenomenon, as these 
women are not systemically immunosuppressed.
It may be, however, that these findings are the result of an immunomodulatory 
process. We know that factors produced by neurones can potentiate expression of
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nerve growth factor and downregulate expression of inflammatory associated 
cytokines, TNFa and IL-1 (3 (Zhang and Fedoroff 1998). If there is neural proliferation, 
one assumes there will be increased neural growth factor, which can suppress 
cytokine production. This would complete the loop of this explanation, and again is an 
area for future exploration.
The explanation for women with VVS being unable to locally produce a normal 
reaction in the vestibule could again be applied to the lack of ER expression seen in 
this study. Again this result was highly significant, but this work is the first 
investigation of this kind in W S , and so there are no other comparative results in the 
literature.
One of my initial hypotheses, that if oestrogen is an immunomodulator, suppressing 
inflammation, and the lack of ER means that oestrogen is not effective locally, is 
disproved if we now assume W S  is not an inflammatory condition. Moreover, my 
attempts to correlate ER expression with cytokine expression in the samples of 
women with VVS overall did not find any relationship.
As part of a future project, immunohistochemistry using double staining techniques, 
would allow direct comparisons of individual sections, to see if lengths of ER 
expression and cytokine expression were in the same or unrelated areas.
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Another area of future investigation would be analysis in greater detail of the “skip 
lesions”. This phenomenon was also seen to some extent in the cytokine expression, 
where areas changed from positive to negative along the same length of epidermis. It 
would also be of value to see whether the areas of lymphocytic infiltration seen in the 
H&E sections, bore any relationship to the position of cytokine expression.
In view of the positive correlation between ER expression and the ability of the subject 
to respond to topical oestrogen, it may be worth considering whether vestibular biopsy 
and immunohistochemistry become part of the routine assessment of women with 
VVS.
The scientific investigation and published literature relating to W S  is expanding.
Studies have shown that this is not primarily a psychological condition, but as with any 
chronic pain syndrome these factors are obviously important. The question is whether 
these psychological features are a predisposition, causative, or a result of the disease. 
Whatever the psychological input, there is no doubt that VVS is a physical syndrome.
Early studies focussed on the pathology and searched for a single aetiological factor. 
The fact that so many studies are conflicting, and no single aetiological factor has 
been found, implies that instead of being a single condition, W S  may be the result of 
a heterogeneous series of events.
If this is the case, then this would explain why treatments have varied success.
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Virtually every conceivable treatment modality has been used in the management of 
VVS, and even using similar protocols, results appear to vary between investigating 
groups.
Although surgery appears to be mainly successful, with most groups quoting success 
rates around 80 -  90%, it is the most invasive option and therefore not to be used as 
first line therapy. The need for a successful non invasive medical therapy is 
highlighted and should be the ultimate aim for clinicians involved in research in this 
area.
Achieving this aim, however, may not be possible until we understand the mechanism 
behind the disease process. Too many treatments are randomly applied, without a 
logical reason for doing so. For example, there is no longer convincing evidence 
regarding HPV involvement in the pathogenesis of W S, and therefore to inflict painful 
interferon injections on women is not appropriate.
A clear distinction should be made between providing symptomatic relief and trying to 
cure the underlying problem. However, it should be recognised that for many of these 
women, who have been suffering for a number of years, a diagnosis and alleviation of 
symptoms, albeit temporary, may come as welcome respite.
More recently, the parameters of investigation have been widened. The role of 
molecular research techniques is beginning to emerge and this may hold the key to 
solving the problem of W S .
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The work looking at inflammatory markers by Foster and Hasday (1997) was the first 
of its kind to be published, at the same time as the initial work in this thesis was being 
performed. Work looking at other inflammatory markers (Bohm-Starke et al 2001, 
Slone et al 1999) has contributed to challenging the initial assumptions about the 
condition as an inflammatory process.
Genetic work (Jeremias et al 2000) is still in the preliminary stages, but no doubt will 
be expanded upon.
Recent work considering the neuroanatomy of the vestibule (Bohm-Starke et al 
1998,1999, Warner et al 1996, Westrom et al 1998) is of interest, and the theories 
produced as a result of these studies again provide evidence that further molecular 
work is required.
The problem with most of these trials is that they are performed by individual units, 
with small numbers of patients, and are uncontrolled. It is therefore difficult to achieve 
statistically significant results. The need for greater collaboration and multicentred, 
controlled trials is paramount. Unfortunately, vulval disease has never been a high 
profile area of gynaecology, compared to oncology, infertility and incontinence.
The establishment of associations such as the BSSVD.ECSVD and ISSVD 
(British,European and International Societies for the Study of Vulvovaginal Disease) 
has helped to start encouraging national and international sharing of ideas and patient 
groups, and hopefully will lead to increased collaboration towards a common goal.
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Certainly it appears there will not be a single explanation for W S . I believe this is a 
heterogeneous syndrome, borne out by the fact that there appear to be subsets of 
women who respond to different treatments. It is certainly possible that women who 
respond to topical oestrogen have a different pathology to women who respond to 
topical corticosteroids, plus tetracycline. Although I feel that the theory of abnormal 
neuroanatomy could explain the group of patients who respond to tricyclic 
antidepressants, or surgery, perhaps a different explanation, or explanations, is 
needed for those who respond to medical treatment.
In conclusion, the studies within this thesis have succeeded in assessing 
characteristics of our study population and proving there is an objective form of 
assessment available for women with VVS. They have succeeded in showing that 
W S  is not an inflammatory condition, and there may be a hormonal component 
involved.
However, this work has also succeeded in creating more questions and suggesting 
further avenues for research to be explored in this complex condition.
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Appendix 1 Revised Classification of Vulvar Disease flSSVDl
1. INFECTIONS
Parasitic e.g. Pediculosis, scabies
Protozoal e.g. amoebiasis
Viral e.g. herpes virus infection, condyloma acuminata
Bacterial
Fungal e.g. candidosis, dermatophytosis
Others
2. INFLAMMATORY SKIN DISEASE
Spongiotic disorders
Contact dermatitis 
Irritant 
Allergic
Atopic dermatitis (acute and chronic)
Seborrheic dermatitis 
Others 
Psoriasiform disorders
Lichenification (Lichen simplex)
Atopic dermatitis (chronic)
Seborrhoeic dermatitis 
Others 
Lichenoid disorders
Lichen sclerosus 
Lichen planus 
Fixed drug eruption 
Plasma cell vulvitis
Lichenoid reaction, not otherwise specified (focal or diffuse) 
Lupus erythematosus 
Others 
Vesicobullous disorders 
Pemphigoid 
Pemphigus 
Erythema multiforme 
Stevens Johnson Syndrome 
Others 
Granulomatous disorders 
Non-infectious:
Sarcoidosis 
Crohn's disease 
(Hidradenitis suppurativa)
Others
Infectious:
Tuberculosis 
Granuloma inguinale
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Vasculitis or related inflammatory disorders 
Leukocytoclastic 
Urticaria 
Aphthous ulcer 
Lymphoedema 
Behcet's disease 
Pyoderma gangrenosa 
(Fixed drug eruption)
(Erythema multiforme)
(Stevens Johnson Syndrome)
3.SKIN APPENDAGES DISORDERS 
Hidradenitis suppurativa 
Fox - Fordyce disease 
Disorders of sweating
4.HORMONAL DISORDERS 
Oestrogen
Excess - Precocious puberty 
Others 
Deficiency
Physiological
Lactation
Post menopausal
Others
Iatrogenic
Androgen
Excess - Physiological 
Iatrogenic
5. ULCERS AND EROSIONS
(Diseases that ulcerate and/or erode are listed according to histologic findings) 
Trauma
Obstetric
Surgical
Sexual
Accidental
Others (include fissures of the fossa navicularis)
6.DISORDERS OF PIGMENTATION
Hyperpigmentation
Melanin
Lentigo
Melanosis vulvae (post inflammatory pigmentation)
Haemosiderin (post inflammatory pigmentation)
Vitiligo
Hypopigmentation
Vitiligo
Post inflammatory pigmentation
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Appendix 2 - Immunohistochemistrv protocols
Oestrogen Receptors
1 Deparaffinise in xylene for 5 mins x3
2 Rehydrate in methanol for 5 mins x 3
3 Wash in distilled water (DDW) for 3 mins x 3
4 Wash in Phosphate Buffered Saline (PBS) for 3 mins x 2
5 Block endogenous peroxidase in 10% H202:
(30ml hydrogen peroxide in 270ml DDW)
Leave for 8 -  10 mins
6 Wash in PBS for 3 mins x 2
7 Microwave in citric buffer on full power for 20 mins
8 Allow citric buffer to cool for 30 mins
9 Wash in DDW for 3 mins
10 Block non specific binding with normal rabbit serum (NRS)
Allow 250|nl per slide dilution = 250 x number of slides 
NRS= Total -10 /. PBS-SAB = total -  NRS
11 Pipette on to slides in 125pl quotients
Leave for 15 mins
12 Add primary antibody (Monoclonal mouse anti-human ER Dako M7047, 
Clone 1D5) in dilution 1:50
PBS-SAB only added to negative control
Incubate for 1 hour in humidity chamber at room temperature
13 Wash in PBS for 3 mins x 3
14 Add secondary antibody (Rabbit anti-mouse biotin,) at dilution 1:200, diluted 
in PBS with 10% normal human serum
Leave for 30 mins
15 Wash in PBS for 3 mins x 3
16 Add Streptavidin biotin complex (StreptABC/HRP Dako Duet kit K0492) 
diluted 1:200 in TBS
Leave for 30 mins
17 Wash in PBS for 3 mins x 3
18 Incubate DAB (180mg DAB, 1000pl imidazole, 30 ml TBS, 260 ml DDW, 
120pl hydrogen peroxide)
Leave for 8 -  12 mins
19 Wash in tap water
20 Counterstain with Mayers haemalum
21 Wash in DDW until clean
22 Wash in acid alcohol
23 Place in blueing solution
24 Dry
25 Glue coverslips onto slides
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Tumour Necrosis Factor Aloha
1 Deparaffinise in xylene for 5 mins x3
2 Rehydrate in methanol for 5 mins x 3
3 Wash in distilled water (DDW) for 5 mins x 2
4 Block endogenous peroxidase in 3% H202:
Leave for 20 mins
5 Wash in TBS for 5 mins x 2
6 Block non specific binding with normal rabbit serum (NRS)
Allow 250pl per slide
7 Pipette on to slides in 125pl quotients
Leave for 10 mins
8 Add primary antibody (monoclonal TNFa -  Santa Cruz Sc-7317, Clone 1E8-
G6) in dilution 1:5
PBS-SAB only added to negative control
Incubate overnight at room temperature in humidity chamber
9 Wash in TBS for 5 mins x 2
10 Add secondary antibody (Rabbit anti-mouse Dako E0354) 1:200, diluted in 
TBS
Incubate for 45 mins at room temperature in humidity chamber
11 Wash in TBS for 5 mins x 2
12 Add Streptavidin biotin complex (StreptABC/HRP Dako Duet kit K0492)
diluted 1:200 in TBS
Leave for 45 mins
13 Wash in PBS for 5 mins x 2
14 Incubate DAB (180mg DAB, 1000pl imidazole, 30 ml TBS, 260 ml DDW,
120pl hydrogen peroxide)
Leave for 10 mins
15 Wash in DDW for 5 -  10 mins
16 Incubate DAB (180mg DAB, 1 OOOjliI imidazole, 30 ml TBS, 260 ml DDW,
120pl hydrogen peroxide)
Leave for 8 -  12 mins
17 Wash in DDW
18 Counterstain with Mayers haemalum
19 Wash in DDW until clean
20 Wash in acid alcohol
21 Place in blueing solution
22 Wash in tap water
23 Dehydrate in methanol for 5 mins x 2
24 Clear in xylene
25 Mount in DPX mountant
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Interleukin 1 beta
1 Deparaffinise in xylene for 5 mins x3
2 Rehydrate in methanol for 5 mins x 3
3 Wash in distilled water (DDW) for 5 mins x 2
4 Block endogenous peroxidase in 3% H202, diluted 1:10
Leave for 10 mins
5 Wash in TBS for 5 mins x 2
6 Block non specific binding with normal goat serum (DAKO X0907), diluted in 
TBS Allow 250pl per slide
7 Pipette on to slides in 125pl quotients
Leave for 20 mins
8 Add primary antibody (Rabbit polyclonal -  Santa Cruz Sc-7884) in dilution
1:100 PBS-SAB only added to negative control
Incubate overnight at room temperature in humidity chamber
9 Wash in TBS for 5 mins x 2
10 Add secondary antibody (Goat anti-rabbit Dako K1492) 1:200, diluted in
TBS Incubate for 45 mins at room temperature in humidity chamber
11 Wash in TBS for 5 mins x 2
12 Add Streptavidin biotin complex (StreptABC/HRP Dako Duet kit K0492) 
diluted 1:200 in TBS
Leave for 45 mins
13 Wash in tap water
14 Counterstain with Mayers haemalum
15 Wash in DDW until clean
16 Wash in acid alcohol
17 Place in blueing solution
18 Wash in tap water
19 Dehydrate in methanol for 5 mins x 2
20 Mount in DPX mountant
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Interleukin 1 alpha
1 Deparaffinise in xylene for 5 mins x3
2 Rehydrate in methanol for 5 mins x 3
3 Wash in distilled water (DDW) for 7 mins x 2
4 Block endogenous peroxidase in 10% H202:
(30ml hydrogen peroxide in 270ml DDW)
Leave for 10 mins
5 Wash in PBS for 3 mins x 2
6 Block non specific binding with normal rabbit serum (NRS)
Allow 250|iil per slide dilution = 250 x number of slides 
NRS= Total +10 PBS-SAB = total -  NRS
7 Pipette on to slides in 125pl quotients
Leave for 10 mins
8 Add primary antibody (Monoclonal IL-1a, Santa Cruz Sc-9983, Clone B7) in 
dilution 1:20
PBS-SAB only added to negative control 
Incubate overnight at room temperature
9 Wash in PBS for 3 mins x 3
10 Add secondary antibody (Rabbit anti-mouse biotin IgM Dako E0354) in 
dilution 1:200, diluted in PBS with 10% normal human serum
Leave for 45 mins at room temperature
11 Wash in PBS for 3 mins x 2
12 Add Streptavidin biotin complex (StreptABC/HRP Dako Duet kit K0492) 
diluted 1:200 in TBS
Leave for 30 mins
13 Wash in tap water
14 Counterstain with Mayers haemalum
15 Wash in DDW until clean
16 Wash in acid alcohol
17 Place in blueing solution
18 Wash in tap water
19 Dehydrate in methanol for 5 mins x 2
20 Mount in DPX mountant
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Immunohistochemistrv: Reagents and Buffers
Xylene
Merck, ‘Analar’ 102936H 
Methanol
Merck Analar’ 101586B 
Hydrogen Peroxide Solution
Add 10 ml 30% hydrogen peroxide (Merck ‘Analar’ 101284N) to 90ml distilled water. 
Final concentration = 3%
Phosphate buffered saline (PBS)
Dissolve 5 PBS sachets (ICN 17-604-20) in 51 distilled water. Check pH.
Sodium Citrate Buffer
Weigh out 2.1g citric acid monohydrate (Merck ‘Analar’ 100813M) add 950ml distilled 
water and 13ml 2M NaOH (Merck ‘Analar’ 1913833x). Make up to 11. Adjust pH 6.0. 
Store at 4°C.
PBS-SAB
Weigh out 100mg bovine serum albumin (Fraction V, Sigma A-2153) and dissolve in 
100ml PBS.
0.1%. Store at 4°C.
Normal Rabbit Serum (NRS)
Dako X0902
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Normal Goat Serum (NGS)
Dako X9070
Normal Human Serum (NHS)
Withdraw 9ml blood into serum tube. Allow to clot at 1 hour at room temperature. 
Centrifuge (Centaur 2300rpm, 1800g) for 15 min. Remove supernatant. Heat at 56°C 
for 30 min (water bath) to denature complement. Store at -20°C in 500pl aliquots in 
Eppendorfer tubes
Tris-Buffered Saline (TBS)
Weigh out 43.83g NaCI (Merck GPR 301235Q) and 30.6g Tris base (Merck ‘Aristar’ 
452054C). Make up to 51 with distilled water. Add 35ml of concentrated HCI (Merck 
‘Analar’ 101250D) to ensure pH is at 7.6 (in fume cupboard). Store at 4°C.
0.05M Tris-HCI, 0.15M NaCI pH 7.6
Imidazole solution
Add 0.681 g imidazole (Merck GPR 285466K) to 100ml distilled water. Store at 4°C. 
0.1 M imidazole solution 
Diaminobenzidine (DAB) solution
Add 180mg of 3,3’-diaminobenzidine tetrahydrochloride (Sigma D-5637) to 270ml 
distilled water, 30ml TBS, 1ml imidazole solution. Add 120pl hydrogen peroxide just 
before use.
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1% Acid-Alcohol
1400ml ethanol (Hayman ‘Absolute Alcohol 100’), 580ml distilled water, 20ml 
concentrated HCI (Merck ‘Analar’ 10125QD
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Appendix 3 Epidemiology questionnaire
Name 
Address 
Date of birth 
SYMPTOMS
1 .When you first developed your symptoms, which of the following did you have and 
how bad were they on a scale of 1 -  10 with 10 being the worst? (please circle)
Burning 0 1 2 3 4 5 6 7 8 9  10
Itching 01 2 3 4 5 6 7 8 9  10
Pain at intercourse 01 2 3 4 5 6 7 8 9 1 0
Discharge 01 2 3 4 5 6 7 8 9 1 0
Tampon difficulty 01 2 3 4 5 6 7 8 9 1 0
2.With regard to your current symptoms, which of the following do you have and how 
bad are they on a scale of 1 -  10 with 10 being the worst? (please circle)
Burning 0 1 2 3 4 5 6 7 8 9 10
Itching 0 1 2 3 4 5 6 7 8 9 10
Pain at intercourse 0 1 2 3 4 5 6 7 8 9 10
Discharge 0 1 2 3 4 5 6 7 8 9 10
Tampon difficulty 0 1 2 3 4 5 6 7 8 9 10
3. Do you think anything precipitated your symptoms? If yes, please specify
4. Are your symptoms constant or intermittent?
5. When are your symptoms worse? Please circle 
During period
Before period 
After period 
Mid cycle
No relation to period
6. What treatments have you had previously?
7. Have any of these treatments been successful? If so please specify.
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CONTRACEPTION
8. What are you currently using as contraception?
9. How long have you used this?
10. What have you used as contraception in the past?
11. Did your symptoms alter when you changed contraception? If yes please specify. 
SEXUAL HISTORY
12. How old were you when you first had sexual intercourse?
13. How many sexual partners have you had?
14. How long have you been with your current partner?
15. Did you have symptoms with a previous partner?
16. How many times per week do you have intercourse
17. If you are not having intercourse is this because it is too painful?
PERIODS
18. When was your last period?
19. How long is your cycle and how long do they last?
20. Are your periods regular?
21. If you do not have periods any longer, did they used to be regular?
22. If your periods are regular, is this because you on taking the pill?
23. Are your periods painful?
24. Do you use tampons? If not, is this because of choice, or because it is too 
painful?
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25. When was your last smear?
25. Have you ever had an abnormal smear? If so please specify.
YOUR PREGNANCIES
26. Please state how many of the following you have had: 
Children
Miscarriage
Termination
Ectopic
27. How many of the following deliveries have you had? 
Normal
Caesarean
Forceps
Ventouse (suction)
28. Did you have a cut or a tear?
29. Did you have problems with your wound after delivery?
30. Did you breast feed? If yes, for how long?
31. How long after your baby did you resume sexual intercourse? 
PREVIOUS MEDICAL PROBLEMS
32. Have you had any illnesses or operations? Please specify.
33. Have you ever had any gynaecological problems? If yes please specify.
34. Have you ever had any of these infections?
Thrush
Chlamydia
Warts
Herpes
Trichomonas
Gonorrhoea
Bacterial Vaginosis
35. Do you have other skin problems?
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GENERAL
36. Does diet affect your symptoms?
37. Does anything run in the family?
38. Are you allergic to anything? If so please specify.
39.1s there anything else that you think is relevant to your symptoms?
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